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PEDIATRIC PULMONARY ARTERIOVENOUS MALFORMATIONS: CLINICAL 
MANIFESTATIONS AND EMBOLOTHERAPY 
Ashraf Thabet1, Marie E. Faughnarr, Meir-Mei Zahav3, Peter Chait4, Robyn A. Pugash5, 
Katharine J. Henderson1, and Robert I. White, Jr.1 Yale Vascular Malformation Center, 
Yale University School of Medicine, New Haven, CT; “Department of Respiratory Medicine, 
HHT Center, St. Michael’s Hospital and the University of Toronto, Toronto, Canada; 
’Respiratory Division, HHT Research Laboratory, and 4Division of Image Guided Therapy, 
Hospital for Sick Children and the University of Toronto, Toronto, Canada; Department of 
Medical Imaging, 5Sunnybrook and Women’s College Health Sciences Centre and the 
University of Toronto, Toronto, Canada. 
The clinical manifestations of pulmonary arteriovenous malformations (PAVMs) and 
the safety and efficacy of transcatheter embolotherapy (TCE) in children were elucidated. 
A review of the literature was undertaken to better define the current understanding 
of how PAVMs manifest in children. A retrospective review of 42 children with PAVMs 
treated with TCE at three centers was performed and outcomes examined, with a mean 
follow-up of seven years. 
Of 130 reported children with PAVMs, paradoxical neurologic embolization (PNE) 
occurred in 4%, cerebral abscess in 5%, and PAVM rupture in 11 %. Five of eight patients 
with massive hemoptysis died. 
Of 42 children treated with TCE, 55% were female. Mean age was 12 years (range: 4- 
18 years). HHT was diagnosed clinically in 85%. PNE occurred in 18%, cerebral abscess in 
5%, and minor hemoptysis in 2%. PAVMs were focal in 71% and diffuse in 29%. TCE was 
performed for 174 AVMs and 35 regions in 76 sessions. Follow-up was obtained in 93% of 
patients. There was a significantly greater incidence of cyanosis, clubbing, and cerebral 
abscess in the diffuse versus the focal group (p<0.05). Mean oxygen saturation was 
significantly greater post- versus pre-TCE in both groups (p<0.0001). Reperfusion was 
noted in 15% of PAVMs and 0% regions (45% of patients). A new mechanism underlying 
persistence of the venous sac after TCE, collateral perfusion, was identified. Eighteen/23 
(78%) of reperfused lesions were retreated with TCE, with documented involution in 14/18 
(78%). One cerebral abscess occurred in the follow-up period. The predominant 
complication of TCE was self-limited pleurisy in 24% of sessions. 
Neurologic and hemorrhagic complications impart significant morbidity and 
mortality in children with PAVMs. A higher rate of PAVM growth during adolescence 
warrants more frequent follow-up than in adults. TCE is a safe and effective treatment 
modality that can be repeated when new PAVMs grow. 
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Pulmonary arteriovenous malformations (PAVMs), first described by Churton in 
1897, are dilated, thin-walled vessels that replace normal capillaries between the pulmonary 
artery and vein (1). The presence of these dilated vessels results m shunting of deoxygenated 
blood into the left-side of the heart and subsequendy, systemic circulation. Because of the 
consequent hypoxemia, the classical description of a patient with PAVMs includes cyanosis, 
clubbing, and dyspnea. 
It appears that many patients with PAVMs acclimate well to hypoxemia, as low- 
altitude dwellers do when they move to higher altitudes (2). This acclimation is likely 
secondary to the increased cardiac output and polycythemia sometimes seen in these 
patients. In the most recent Mayo Clinic series of 93 patients with a mean age of 40 years, 
cyanosis was present in only 29% and clubbing in 19%, although dyspnea was present in 
57% (3). 
Less frequently, the dilated, thin-walled aneurysmal portion of PAVMs may rupture, 
leading to life-threatening pulmonary hemorrhage. In a series of 76 patients with 276 
PAVMs and a mean age of 36 years, 13% of patients suffered hemoptysis and 9% 
hemothorax (4). In another series of 143 patients with PAVMs, 11 patients suffered massive 
hemoptysis or hemothorax requiring hospitalization: in nine patients, hemorrhage was the 
first symptom of PAVMs (5). In five of 11 patients, massive hemoptysis resulted in one 
death, two lobectomies, and one emergency caesarean section. Spontaneous hemothorax 
occurred in another five patients requiring tube thoracostomy or multiple thoracenteses 
while in one patient, both massive hemoptysis and hemothorax occurred at age 24 and 33 
years, respectively. Based on the two aforementioned studies, it is clear spontaneous 
hemorrhage of a PAVM is a serious and life-threatening event. 
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In the last three decades, a more common presentation of PAVMs became 
increasingly recognized. The loss of filtering capacity provided by pulmonary capillaries 
effectively produces a conduit through which paradoxical emboli may pass through into the 
systemic arterial circulation, causmg catastrophic neurologic sequelae such as stroke and 
cerebral abscess. Neurologic complications occur in approximately 40% of adults with 
PAVMs despite few, if any, limiting respiratory symptoms (4, 6). In one consecutive series of 
75 patients with PAVMs consisting of a feeding artery (FA) diameter of at least 3 mm, 13% 
had a history of a cerebral abscess, 44% had a transient ischemic attack or clinical stroke, and 
51% had radiological evidence of cerebral infarct (7). Clinical embolic events appear to be 
common when the FA diameter to PAVMs is equal to or greater than 3 mm (4, 7, 8, 9). It is 
important to recognize, however, that cerebral abscess may still occur in patients with a FA 
diameter less than 3 mm after bacteremic procedures (e.g., dental work), necessitating 
antibiotic prophylaxis for such procedures. 
Over two-thirds of patients with PAVMs have Flereditary Hemorrhagic 
Telangiectasia (HHT), also known as Osler-Weber-Rendu Syndrome (4, 10, 11). An 
autosomal dominant generalized vascular dysplasia, patients with HHT often exhibit 
epistaxis, mucocutaneous telangiectases, and manifestations of visceral AVMs, including 
those of the lungs (12), brain (13), liver (14, 15), GI tract (16) and rarely, the spinal cord (17), 
retina (18), spleen (19), pancreas (19), bladder and urethra (20). PAVMs may also be sporadic 
or may be associated with trauma (21) or the hepatopulmonary (22) and polysplenia (23) 
syndromes. 
HHT is a genetically heterogeneous disorder. A mutation in the endoglin gene, located 
on the long arm of chromosome 9 (24, 25), underlies HHT type 1, while a mutation in the 
gene encoding activin-like kinase 1 (ALK-1), located on the long arm of chromosome 12 (26, 
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27), underlies HHT type 2. A third yet unidentified gene has also been implicated (28). 
PAVMs, cerebrovascular malformations, intrahepatic shunting, and bleeding GI 
telangiectases have been observed in both HHT types. It is believed, however, that PAVMs 
may be more frequent in HHT type 1, while the ALK-1 mutation may be associated with 
lower disease penetrance, milder phenotype, and later age of onset (26, 29-34). The clinical 
diagnosis of HHT is made according to the Curacao criteria (35), and must include at least 
three of four features: 1) spontaneous recurrent epistaxis, 2) mucocutaneous telangiectases, 
3) visceral AVMs or telangiectases, and 4) positive family history of HPIT. The presence of 
two criteria makes a possible or suspected diagnosis, while fewer then two criteria is 
considered unlikely for HHT. As of December 2003, a clinical DNA test for HHT has 
become available, making it possible to confirm suspected diagnoses. 
Endoglin and ALK-1 are members of the TGF-(3 receptor superfamily. In the 
extracellular space, TGF-f3 receptor ligands bind either the type II receptor or an accessory 
protein (endoglin) that presents the ligand to the type II receptor (36-38). Binding of the 
ligands to the type II receptor leads to the formation of a heteromultimeric complex with the 
type I receptor (ALK-1), resulting in the activation of a phosphorylation cascade of 
intracytoplasmic messengers (SMADs), and consequent modulation of gene transcription 
(36-38). Studies have demonstrated that approximately 50% of normal levels of endoglin are 
expressed in both AVM and normal endothelial tissue in HHT type 1 patients (45). It is not 
yet known whether a haploinsufficiency model, dominant-negative effect, second-hit event, 
or a combination thereof, best explains the clinical manifestations of HHT (38). 
Along with genetic heterogeneity there is a remarkable phenotypic variation among 
and within families with HHT. The overall disease prevalence appears to be greater than one 
in 10,000 persons and is as high as one in 2,351 persons m the Ain region of France (39-43). 
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There is at least one case report of a child born to parents, each with a positive family history 
of HHT, who may have been homozygous for HHT (although no molecular analysis was 
available); the child rapidly developed generalized telangiectases, appearing each day, and 
died at two and half months from severe anemia (44). 
The most common manifestation of HHT is epistaxis, affecting approximately 93% 
of patients (46). About 54% experience onset by age 10 years, 90% by age 20 years, and few 
have onset after age 30 (46). The severity of nosebleeds vary considerably—28% of patients 
describe their epistaxis as mild, 54% as moderate (bothersome but not limiting), and 18% 
experience severe nosebleeds that limit their activities (46). GI bleeding, predominantly 
resulting from telangiectases within the stomach, duodenum, and small intestine, usually 
appear in the fifth and sixth decades and affect anywhere from 13-44% of patients (16, 47). 
Recurrent bleeding from nose and/or GI telangiectases may explain the absence of 
polycythemia m patients who have hypoxemia associated with PAVMs. 
Cerebral vascular malformations occur in 10-23% of patients with HHT (13, 48). 
Analyzing data from 22,061 HHT patient-years, Easey and colleagues determined that 
cerebral hemorrhage was 20 times more likely in the male HHT population aged 45 years or 
less than in the general population; females were six times more likely to suffer a cerebral 
hemorrhage (49). The rate of cerebral hemorrhage in HHT patients with CAVMs was 1.4- 
2.0% per annum, comparable to figures in the non-HHT CAVM population (49). 
PAVMs arise at any point in a patient’s lifetime, and growth of untreated AVMs (Fig. 
1) has been documented (50, 51). The degree of pulmonary involvement varies 
considerably. A patient may have a single discrete PAVM, multiple discrete PAVMs in one 
or more lobes, or diffuse PAVMs, defined as involvement of every subsegmental artery in at 
least one lobe (21). Approximately 60% of patients with HHT have multiple PAVMs, 
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whereas patients with idiopathic lesions typically have a single PAVM (10, 52, 53). As clinical 
DNA test results are studied, the reasons for these phenotypic differences may become 
more apparent. In approximately 61% of patients in a predominantly adult series, PAVMs 
were noted to be preferentially located in the lower lobes, consistent with clinical 
observations of platypnea (difficulty breathing m the erect position, but relieved with 
recumbency) and orthodeoxia (4, 10, 46, 52-55). 
The angioarchitecture of PAVMs has been extensively studied in adults (4, 56-60). A 
PAVM is considered simple when it is fed by one or more branches from the same 
pulmonary segmental artery. If more than one segmental artery contributes feeders, the 
AVM is considered complex. This distinction is extremely important when performing 
embolotherapy, as will be discussed. Approximately 55% of patients have simple PAVMs, 
40% have both simple and complex, and 5% have diffuse involvement (3, 57). The 
aneurysmal connection between the pulmonary artery and vein in simple PAVMs are 
typically nonseptated, whereas complex PAVMs typically have circsoid and septated 
aneurysmal connections (57). 
Because a majority of patients with PAVMs have HHT, and given that HHT patients 
are at risk of developing new PAVMs throughout their lifetimes, a non-invasive sensitive 
screening technique is critical. Contrast echocardiography is a simple, safe, nonmvasive, 
widely-available screening tool with a low false-negative rate, no radiation, and sensitivity 
greater than 90% (61, 62). The technique involves injection of an agitated saline solution 
durmg echocardiography; visualization of microbubbles in the left atrium at least three 
cardiac cycles after their appearance m the right atrium is positive for pulmonary 
arteriovenous shunting (61, 62). Prespecification of bubbles appearing in the left atrium after 
three cardiac cycles is important to exclude intracardiac shunting due to a patent foramen 
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ovale, atrial septal defect, or ventricular septal defect. It is believed that patients with echo 
studies positive for PAVMs but with negative subsequent pulmonary angiograms likely have 
microAVMs (61). Such microAVMs would not be expected to allow climcally-sigmficant 
paradoxical emboli into the systemic circulation, although hypoxemia and the risk of cerebral 
abscess may exist. 
Coil or balloon embolization of feeding arteries is currently the standard of treatment 
of PAVMs in adults (2, 4, 5, 8, 56, 57, 60, 63, 64). The technical aspects and outcomes of 
transcatheter embolotherapy (TCE) in adults have been well described (2, 4, 56, 60). 
Reported complications include self-limited pleurisy, air embolus, and paradoxical embolus 
of a device, none of which have led to long-term sequelae (4, 56, 60). The parenchyma¬ 
sparing benefit of TCE versus surgery, combined with lower morbidity and shorter hospital 
stays makes embolotherapy the treatment of choice for most PAVMs, particularly in HHT 
patients who have a genetic predisposition to developmg new malformations throughout 
their lifetimes. 
Statement of Purpose and Hypothesis 
As the clinical DNA test for HHT becomes more widely utilized, it is anticipated 
that many more minimally symptomatic children with HHT will be identified, a substantial 
proportion of whom will have large PAVMs. While the manifestations and treatment of 
PAVMs in adults are well-documented, the clinical presentation in children is less well 
known. The safety and efficacy of TCE have been well documented in adults but data are 
lacking in children. Currently, there are only 12 reports constituting a total of 17 patients in 
the literature documenting the use of TCE in children (2, 56, 63, 65-73). Follow-up was not 
reported in nine of the 17 children reported to date. 

Paradoxical neurologic embolization and life-threatening pulmonary hemorrhage 
were hypothesized to occur with some as yet unknown frequency in the pediatric population. 
There was uncertainity among physicians, caring for HHT families, when and if screening 
for children should occur. Similarly, TCE of PAVMs had not yet been proven safe and 
efficacious in children. 
The purpose of this thesis is several-fold. An extensive review of the English- 
language literature was undertaken to better define how PAVMs manifest in children. A 
retrospective analysis of children seen at two HHT Centers (Yale University and the 
University of Toronto) and at Johns Hopkins Hospital was undertaken. Documentation of 
clinical manifestations as well as the safety and efficacy of embolotherapy was made in the 
study patients in whom there was a mean follow-up of seven years. 
Case Report 
A previously healthy nine-year-old girl in Ireland began to have minor episodes of 
epistaxis. On an outpatient ENT exam two months later, no abnormality was observed. 
Hemoglobin level was 12.3 g/dl. 
Five days later, the patient was hospitalized for profuse nasal and upper-airway 
bleeding. Oxygen saturation was 74% on room air, rising to 95% on 100% oxygen; her Pa02 
on room air was 91 mmHg. Pulse was 150/min and blood pressure was 130/80 mmHg. 
Coagulation studies were normal. Hemoglobin level dropped to 9.8 g/dl, but rose to 13.8 
g/dl after transfusion of one umt of packed red blood cells. Chest radiography demonstrated 
inflammatory changes in the right upper lobe, believed to represent aspiration from epistaxis; 
these disappeared on a follow-up radiograph. ENT examination under anesthesia 
demonstrated a prominent vessel on the right tonsil and raw area in the right mid-septum 

without active bleeding; both were cauterized. Telangiectases were noted on the face, right 
thigh, right buccal mucosa, and right lingual tonsil. There was a history of epistaxis and 
cutaneous telangiectases in the father, paternal grandmother, and paternal great¬ 
grandmother. A diagnosis of HHT was considered. The patient was discharged with an 
outpatient clinic appointment to further work-up the possibility of HHT. 
Two weeks later, the patient was readmitted for hemoptysis. Oxygen saturation was 
85% on room air and 94% while breathing 100% oxygen. A right upper lobe shadow on 
chest radiograph was again seen; the patient was stabilized and discharged awaiting her clinic 
appointment. 
Patient visited the pediatric outpatient department one and half months later. She 
was having 1-2 episodes of light epistaxis per week and complained of dyspnea after long 
walks. The possibility of a pulmonary arteriovenous malformation was considered and a 
referral to an HHT center was recommended. No cerebrovascular malformations were 
noted on cranial MRI two weeks later. 
The patient was re-admitted two more times over the next four and one-half months 
with minor hemoptyses. New telangiectases were noted on her face and right wrist. On her 
fourth admission, chest radiography demonstrated a right upper lobe density as well as an 
mcreased cardiothoracic ratio and enlarged main pulmonary artery compared to previous 
studies. An electrocardiogram demonstrated right axis deviation and right ventricular 
hypertrophy. 
Twelve days after her fourth admission and two weeks prior to an appointment at a 
HHT center, the patient collapsed at home with massive hemoptysis, leading to hemorrhagic 
shock and asphyxiation. She arrived at the emergency department in full cardiac arrest; 
resuscitation efforts were unsuccessful and the patient died. 
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On autopsy, a ruptured two-centimeter right upper lobe pulmonary arteriovenous 
malformation was identified. Intrmal fibrosis, medial hypertrophy, and plexiform lesions of 
pulmonary arteries and arterioles were observed on histology, consistent with Grade IV and 
V Heath Edwards changes of pulmonary hypertension. 
Twenty-six family members underwent clinical evaluation for HHT. A clinical 
diagnosis of HHT was definite in 13/26 (50%) and suspected in 6/19 (23%) individuals. An 
additional family member was not screened but had a history of PAVM. Of 17 individuals 
who underwent contrast echocardiography, nine (53%) were positive. Eight of these nine 
had normal oxygen saturations and six had PAVMs detectable on chest CT. Two of the six 
patients had feeding arteries with a diameter > 3 mm. On pulmonary angiography, one 
PAVM was detected each in the great uncle of the proband and another in her 40-year old 
aunt. Both patients had normal pulmonary arterial pressures and underwent successful 
embolization with metal coils. No cerebral AVMs were found in the 18 family members 
who underwent brain MRI. 
Subsequent DNA analysis demonstrated a mutation in the ALK-1 gene, consistent 
with HHT type 2. 
Subjects and Methods 
Uterature Review 
All case reports of children with pulmonary arteriovenous malformations were 
searched using Medline. Reports prior to 1966 were found by examining references of 
reviews and reports published after 1966. Only reports in which patients were aged 18 years 
or younger were included. 
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Reports were reviewed and the following data collected: age, gender, specific 
diagnosis of HHT reported, family history of HHT, manifestations of HHT (epistaxis, 
mucocutaneous telangiectases, AVMs of the lung, brain, spinal cord, liver, GI tract), signs 
and symptoms of PAVMs (dyspnea on exertion/exercise intolerance, cyanosis, clubbing, 
polycythemia), complications of PAVMs (hemoptysis, hemothorax, clinical stroke, transient 
ischemic attack, cerebral abscess), cerebral hemorrhage, oxygen saturation (room air, 
supplemental oxygen), arterial blood gas measurements (room air, supplemental oxygen), 
shunt fractions, hemoglobin level, hematocrit, intervention (surgery, TCE), results of 
intervention, and follow-up when available. 
Subject Selection 
Of 617 patients with pulmonary arteriovenous malformations treated with 
transcatheter embolization at the Johns Hopkins Hospital (1978-1988), Yale Vascular 
Malformation Clinical and Research Center (1988-2003), and the University of Toronto 
HHT Center (1990-2003), 42 consecutive patients aged 18 years or less were included. One 
interventional radiologist treated patients at the Johns Hopkins Hospital and then the Yale 
Vascular Malformation Clinical and Research Center; after 1988, patients treated at Johns 
Hopkins were followed up at Yale or the University of Toronto. The study period extended 
from 1978 to January 2003. Indications for referral to these centers included suspected 
PAVMs or HHT screening in the asymptomatic patient. 
Medical records and imaging were reviewed and the following data collected: age, 
gender, number and lobar location of treated PAVMs, signs and symptoms of PAVMs 
(dyspnea on exertion/ exercise intolerance, cyanosis clubbing), previous complications of 
PAVMs (hemoptysis, hemothorax, transient ischemic attack, clinical and/or radiologic 
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stroke, cerebral abscess), oxygen saturation before and after embolotherapy, complications 
of TCE, long-terms results of TCE (CT and/or catheter-based angiography), and 
complications of PAVMs on follow-up. 
Focal patients #10 and 11 (Table 6) were previously reported in the literature (56). 
Diffuse patients #1, 2, 3, and 5 (Table 7) were also previously reported in the literature (63). 
This study was approved by the Human Investigations Committees of the Yale 
University School of Medicine and the University of Toronto. 
Classification ofiA.ngioarchitecture 
All patients underwent pulmonary angiography. Pulmonary involvement by PAVMs 
was classified as focal or diffuse. Diffuse PAVMs (Fig. 2) are defined as malformations 
involving every subsegmental artery in at least one lobe (63). The angioarchitecture of focal 
PAVMs were further classified as simple or complex (4, 56). Simple PAVMs (Fig. 3) have 
one or multiple feeding arteries, all originating from the same segmental artery. All complex 
PAVMs (Fig. 4) have at least two feeding arteries, arising from at least two different 
segmental arteries. 
Transcatheter Timbolotherapy 
All feeding arteries with a diameter equal to or greater than 3 mm were treated with 
transcatheter embolization (9). Standard embolic materials were utilized, including stamless 
steel and platinum coils as well as detachable balloons (2, 4, 56, 60, 63, 74, 75). Detachable 
balloons were used under an investigational device exemption and are not FDA approved 
for embolization of PAVMs. Glue was used as an embolic agent in one patient (focal #6) in 
one session of TCE. The technique of embolization is well-documented in adults, and was 
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adopted in the treatment of children with two modifications. First, general anesthesia or 
heavy sedation was used in all children of age 12 years or younger. Second, diagnostic 
angiography and TCE were performed on the same day. As per standard technique, catheter 
exchanges were performed under water to prevent introduction of air that may act as a 
paradoxical embolus (60). 
Diffusely-involved regions of lung were treated in several patients by occluding the 
subsegmental or segmental artery feeding the region by distal to proximal placement of coils. 
In some of these patients with severe hypoxemia, pulmonary flow redistribution as described 
in adults (63) was performed, in which a temporary test occlusion of lobar arteries was 
performed; if the partial pressure of arterial oxygen rose by at least 10 mmHg, permanent 
occlusion of the affected lobe was performed with coils and/or balloons in order to 
eliminate it from the pulmonary circulation. 
To assess successful occlusion of PAVMs, completion angiography was performed 
immediately after TCE, provided contrast media limits had not already been exceeded. 
Oxygen saturation measurements were made pre-TCE and within 24 hours upon completion 
of a session. For prevention of cerebral abscess, patients received antibiotic prophylaxis 
prior to bacteremic procedures, including all sessions of TCE. 
Follow-up 
Assessment of the efficacy of TCE was performed by follow-up 6-12 months after 
each TCE session, and every three years afterwards. Follow-up measures were comprised of 
surveillance with high-resolution helical CT and evaluating for complications of PAVMs or 
TCE. CT was performed with 5 mm cuts, without the use of intravenous contrast media 
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given the theoretical risk of air embolus inherent in establishing intravenous access for 
contrast administration (58, 59). 
Treated PAVMs were evaluated with CT imaging for confirmation of involution, 
defined as thrombosis, retraction, and fibrous scarring of the venous sac connecting the 
feeding artery to the draining vein (Fig. 5). Reperfusion of PAVMs was suspected on CT 
when there was persistence of the venous sac and/or draining vein. Pulmonary angiography 
was performed in patients in which reperfusion of PAVMs was suspected. 
Two mechanisms of reperfusion have been reported in the literature (56). The first 
mechanism has been described as recanalization of a previously embolized feeding artery 
(Fig. 6). This represents a failure of TCE and consists of reperfusion through the original 
coils or reperfusion due to deflation of a detachable balloon (usually within 21 days of TCE). 
The second mechanism of reperfusion is an accessory artery arismg more proximally from 
the same segmental artery or from another segmental artery (56). These arteries supplying 
the PAVM were either too small to occlude during the original session of TCE or were 
undetected at first examination, likely due to the lack of a completion angiogram at TCE. On 
retrospective examination of the original angiograms, these accessory arteries were usually 
detected. 
A third mechanism underlying lack of venous sac involution has been identified 
during follow-up of children in this study. Multiple, tiny (< 1 mm diameter) vessels that 
develop from another segmental artery after TCE and join the venous sac of the treated 




Comparison of the mean oxygen saturations pre- and post-therapy was performed 
using parred t-tests. Two-sample comparison of proportions was used for assessing the 
frequency of signs and symptoms in patients with focal versus diffuse PAVMs. Statistical 
calculations were performed using Microsoft Excel, STATA, and MedCalc software. 
Results 
Literature Review 
From 1897 to 2000, at least 130 patients with PAVMs aged 18 years or younger have 
been reported in 87 English-language publications, including English-language reviews of 
foreign-language papers (1, 2, 5, 10, 34, 45, 48, 54, 57, 63, 65-73, 76-144). There were 61 
boys (47%) and 63 girls (48%); the gender of 6 children (5%) was not reported. Mean age at 
presentation was 8.8 years (range: newborn — 18 years). A diagnosis of HHT was reported in 
34/130 (26%) children. Enough information was reported to make a definite diagnosis of 
HHT based on die presence of at least three of the four Curacao clinical criteria (35) in 18% 
(23/130) of reported children; a diagnosis was suspected (i.e., 2 criteria were met) in 20% 
(26/130). In those patients without definite or possible HHT, occurrence of PAVM was 
considered sporadic. 
The most common manifestation of PAVMs (Table 1) was cyanosis (75%), followed 
by clubbing (54%), dyspnea/exercise intolerance (51%), and reported polycythemia (13%). A 
history of clinical stroke was reported in 2% with a further 2% having experienced transient 
ischemic attacks (hence, 4% had paradoxical neurologic embolic events). Cerebral abscess 
was reported in 5% of children in the literature. Cerebrovascular malformations were found 
in 3% (4/130); one child was reported as suffering a cerebral hemorrhage secondary to CVM 
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rupture. Unidentified neurologic events (e.g. hemiparesis, spastic tetraplegia), in which 
insufficient information was provided to attribute to paradoxical neurologic embolization or 
cerebrovascular malformation, occurred m 5%. 
Reported clinical characteristics that may be attributed to HHT (Table 1) included 
cutaneous telangiectases (25%), epistaxis (13%), and family history of HHT or PAVM 
(22%). Gastrointestinal telangiectases were reported in 3% and liver AVMs or telangiectases 
in 3%. 
Hemoptysis was reported in 9% and hemothorax in 2% (Table 1). This is excluding 
one child who died of massive pseudohemoptysis from multiple tracheobronchial 
telangiectases (123). Hemoptysis in eight of 11 children was reported as massive (Table 2). 
Of these 8 children, five (63%) died, two within 24 hours of the first episode of hemoptysis 
and one within one week. Pulmonary arterial pressures were reported for one child and was 
elevated at 95/10 mmHg (134). That child died during PAVM resection that took place 
after 16 hemoptysis-free days. Hemothorax was reported in three children, two of whom 
died (Table 3). 
Oxygenation data were reported in less than half of the case reports (Table 4). A pre¬ 
procedure oxygen saturation on room air was reported for 44% of children; mean sO, was 
80.4% (range: 55 — 98%). Arterial blood gas data were provided on room air in 19% and on 
100% 02 in 9%; mean PaO, was 46.2 mmHg (range: 35 — 77 mmHg) and 96.6 mmHg 
(range: 32 - 344 mmHg), respectively. A hemoglobin and hematocrit were reported for 50% 
and 36% of children, respectively (Table 4); mean hemoglobin was 16.7 g/dl (range: 9.7 — 24 
g/dl) and mean hematocrit was 53.8 ml/dl (range: 22 - 79.5 ml/dl). The mean shunt 




Intervention was attempted in 79/130 (61%) of reported children. In 62 children, 
surgical intervention in the form of AVM ligation, pulmonary wedge resection, lobectomy, 
and/or pneumonectomy was performed. Seven children eventually died (11%): two intra- 
operatively (134, 135), three immediately post-operatively (79, 88, 97), one two years post- 
operatively from an unspecified cerebrovascular accident (10), and one died after massive 
hemoptysis occurring 10 months after his third operation and four radiotherapy treatments 
for PAVM (85). In 17 children, transcatheter embolotherapy was attempted (13%). Two 
children who underwent TCE died during follow-up: one died seven months post-TCE 
from respiratory infection (80) and another died 10 years post-TCE during lung 
transplantation for severely diffuse disease (63). 
Multi-Center Pediatric PAVM Series 
1. Baseline Characteristics and Clinical Presentation 
Of 42 children with PAVMs who underwent transcatheter embolotherapy at the 
Yale Vascular Malformation Center, Johns Hopkins Hospital, and the University of Toronto 
HHT Center, 23 were female (55%) and 19 were male (45%). Mean age at assessment was 12 
years (range: 4-18 years). PAVMs were focal in 30/42 (71%) of children and diffuse in 12/42 
(29%). 
The most common manifestation of PAVMs (Table 5) was cyanosis (60%), followed 
by dyspnea/exercise intolerance (57%), and clubbing (45%). Minor hemoptysis occurred in 
7% of children. No child suffered a hemothorax. Neurological complications attributed to 
PAVMs (Table 5) occurred in 8/42 patients (19%), including cerebral abscess (5%), transient 
ischemic attack (2%), and MRI-detected cerebral infarct (18%). Of these eight patients, 
seven were cyanotic (88%). The one exception was focal patient #3 (Table 6), who had a 
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“silent infarct” on MRI. Neurological complications occurred in both focal and diffuse 
populations (Table 5). Comparing neurologic complications, including silent infarcts, 
between cyanotic and acyanotic patients, 7/25 cyanotic children (28%) and 1/17 acyanotic 
children (5.9%) experienced a neurologic complication (p = 0.16). 
The frequency of signs, symptoms, and complications was higher in the diffuse 
group versus the focal group (Table 5). However, differences in these frequencies were 
statistically significant (p < 0.05) only for cyanosis (100% vs. 43%), clubbing (75% vs. 33%), 
and cerebral abscess (17% vs. 0%). 
Manifestations of HHT (Table 5) included epistaxis (86%) and cutaneous 
telangiectases (79%). Of the 34 children who had cerebral imaging, cerebrovascular 
malformations were detected in 7/34 (21%) children. Of these seven children, two suffered 
a cerebral hemorrhage (29%). Patients were not screened for liver AVMs except in one 
patient with HHT and diffuse PAVMs who became symptomatic in her fourth decade of life 
(Table 7, diffuse patient #2). No child had clinical evidence of gastrointestinal involvement 
and hence, screening for GI telangiectases was not routinely performed. One patient (focal 
#2) had juvenile polyposis coli. 
According to the Curacao clinical criteria (35), 85% of patients had definite HHT 
(90% of focal and 75% of diffuse patients). Only 5% of patients had a suspected diagnosis 
of HHT (3% of focal and 8% of diffuse patients), based on the presence of only two 
Curacao criteria. Ten percent of patients satisfied only one criterion and their PAVMs were 
considered sporadic. 
Ten patients had undergone TCE or surgery prior to referral (Footnotes: Tables 6 
and 7). The outcomes of these procedures were not analyzed. 
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2. Angiographic Characteristics and TCE 
A total of 174 PAVMs were embolized in 76 sessions (Tables 6 and 7). In the focal 
group (Table 6), 30 patients had a total of 85 PAVMs that were treated with TCE. In the 
diffuse group (Table 7), all 12 patients had innumerable PAVMs, including 89 focal PAVMs 
treated with TCE. In addition to these PAVMs, 35 diffusely-involved regions were treated 
with regional TCE, as described in the Subjects and Methods section. Included in the 
regional embolization category were two patients who underwent pulmonary flow 
redistribution (Table 7, patient #2 and 3). Some sessions required multiple procedures over 
several months, secondary to reaching contrast limits, patient fatigue, and/or necessity for 
further study of angiograms to plan completion of embolization of targeted PAVMs. 
In the focal group, 18/30 (60%) had multiple PAVMs. Sixty-six of 85 PAVMs (78%) 
were simple, 19/85 (22%) were complex, and 62/85 (73%) were located in the lower lobes. 
Fourteen of 30 (47%) patients had only simple PAVMs, 6/30 (20%) had only complex, and 
10/30 (33%) patients had both. Of the discrete PAVMs treated in the diffuse group, 88/89 
(99%) were simple, 1/89 (1%) was complex and 63/89 (71%) were located in the lower 
lobes. Of the subsegmental and segmental arteries embolized during regional TCE, 34/35 
(97%) were located in the lower lobes. 
3. Outcomes of TCE 
Follow-up was obtained for 154/174 PAVMs (89%) and 22/35 (63%) regions 




A. Oxygenation Data: 
In the focal group (Table 6), oxygen saturation (sO^ prior to each session of TCE 
was available for 44/48 sessions; mean s02 was 89.2% (SD = 11.3%; range: 44 — 100%). In 
the diffuse group (Table 7), s02 prior to each session of TCE was available for 26/28 
sessions; mean s02 was 83.3% (SD = 8.2%; range: 62 — 96%). Mean pre-TCE sO, was 
significantly lower in the diffuse group than in the focal group (p = 0.01). Mean pre-TCE 
s02 for all sessions was 87.4% (SD = 8.2%; range: 44 — 100%). Mean s02 prior only to the 
first session of TCE in each diffusely-affected patient (available for 12/12 patients) was 
significantly lower (80.5%; SD = 8.5%; 62 — 89%) than in the focal group (89.4%; SD = 
10.6%; range: 47 — 100%; available for 27/30 patients), with p < 0.01. 
In the focal group (Tables 6 and 8), paired oxygen saturation data were available pre- 
and post-TCE for 42/48 sessions (88%). Mean sO, was 90% pre-TCE (SD = 9.4%; range: 
44 - 100%), compared to 96.6% post-TCE (SD = 4.5%; range: 72 - 100%), with p < 
0.00001. In the diffuse group (Tables 7 and 8), sO, was available pre- and post-TCE for 
26/28 sessions (93%). Mean s02 was 83.3% pre-TCE (SD = 8.2%; range: 62 - 96%), 
compared to 87.8% post-TCE (SD = 7.1%; range: 74 - 97%), with p < 0.0001. For both 
groups (Tables 6, 7, and 8), data was available for 68/76 (89%) sessions. Mean pre-TCE s02 
for both groups was 87.4% (SD = 9.5%; range: 44 — 100%), and post-TCE was 93.2% (SD 
= 7%; range: 72 — 100%), with p < 0.0001. 
Comparison of oxygen saturation prior to the first session of TCE and after the last 
session of TCE for each patient was also performed (Table 8). Paired data were available in 
the focal group for 27/30 (90%) patients. Mean pre-first session s02 was 89.4% (SD = 
10.6%; range: 47 — 100%) and mean post-last session s02 was 97% (SD = 5.2%; range: 72 — 
100%), with p < 0.00001. Paired data were available in the diffuse group for 11/12 (92%) of 
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patients. Mean pre-first session s02 was 80.3% (SD = 8.9%; range: 62 — 89%) and mean 
post-last session TCE was 88.7% (SD = 7.5%; range: 77 — 97%), with p = 0.0005. Overall, 
paired data were available in the total patient population for 38/42 (90%) of patients. Mean 
pre-first session sO, was 86.8% (SD = 10.9%; range: 47 — 100%) and mean post-last session 
s02 was 94.6% (SD = 7%; range: 72 — 100%), with p < 0.00001. 
Comparison of oxygen saturation prior to the first session of TCE and at last follow¬ 
up was performed (Table 8). In the focal group, paired data were available for only 14/30 
(47%) patients, with mean follow-up of 5.4 years. Mean pre-first session sO, was 89.9% (SD 
= 7.2%; range: 75 — 98%) and mean s02 at last follow-up was 97.7% (SD = 1.7%; range: 94 
— 100%), with p = 0.0012. In the diffuse group, paired data were available for 11/12 (92%) 
patients, with mean follow-up of 5.8 years. Mean pre-first session sO, was 80.3% (SD = 
8.9%; range: 62 — 89%) and mean s02 at last follow-up was 86.6% (SD = 8.5%; range: 67 — 
96%), which was not statistically significant (p = 0.053). For the total patient population, 
paired data was available for 25/42 (60%) patients, with mean follow-up of 5.6 years. Mean 
pre-first session sO, was 85.6% (SD = 9.2%; range: 62 — 89%) and mean s02 at last follow¬ 
up was 92.8% (SD = 8%; range: 67 — 100%), with p < 0.0002. 
B. Imaging Follow-Up: 
During the follow-up period, reperfusion was noted on CT scan in 23/154 PAVMs 
(15%) and 0/22 regions (0%) in 17/38 (45%) patients (Table 9). In the focal group, 
reperfusion occurred in 19/74 (26%) PAVMs in 14/27 (52%) patients followed-up with CT 
scan. Three of 30 (10%) patients with three treated PAVMs in the focal group were lost to 
follow-up after only one session of TCE (Table 6, patient # 20, 25, and 27). No follow-up 
was yet obtained for six treated PAVMs in four patients (Table 6, patient #14, 15, 21, 22); all 

six PAVMs were treated recently and are awaiting follow-up scheduled after the end of the 
study period. Two patients (#1 and 9) died prior to follow-up of two PAVMs. 
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Of the three types of reperfusion after TCE described in the Subjects and Methods 
section, 11/19 (58%) PAVMs in 6/14 (43%) focally-affected patients demonstrated 
recanalization (RC) of the previously embolized PAVM on angiography (Table 9). Missed 
accessories (MA) to 7/19 (37%) PAVMs in 5/14 (36%) patients were observed. Collateral 
perfusion (CP) to 12/19 (63%) PAVMs in 10/14 (71%) patients were also observed. Five 
PAVMs in five patients had two types of reperfusion simultaneously observed on 
angiography: two had RC and CP (#3 and 8) and three had MA and CP (#6, 11, and 13). A 
total of six PAVMs in four patients reperfused twice (#6, 7, 8, and 10). 
In the diffuse group, reperfusion of 4/80 (5%) treated PAVMs occurred in 3/11 
(27%) patients (Table 9). CT follow-up was not yet obtained for 3/6 regions in patient #11 
and all 10 treated regions in patient #12 by the end of the study period, although oxygen 
saturation at follow-up remained improved. Recanalization comprised three of four (75%) 
occurrences of reperfused PAVMs in 2/3 (67%) patients (#5 and 7). MA was observed in 
two of four (50%) reperfused PAVMs in 2/3 (67%) patients (#2 and 5). No instance of 
collateral perfusion was observed. One PAVM in diffuse patient #5 had both recanalization 
of a previously embolized feeding artery and missed accessories. 
Overall, recanalization occurred in 14/23 (61%) reperfused PAVMs in 8/17 (47%) 
patients (Table 9). Reperfusion was attributed to MA in 9/23 (39%) PAVMS in 7/17 (41%) 
patients. Collateral perfusion was observed in 12/23 (52%) PAVMs found in 10/17 (59%) 




Only five focal patients with five reperfused PAVMs did not undergo repeat TCE; in 
all cases, collateral perfusion was the underlying cause (Table 9, focal patient #13, 14, 16, 24, 
and 28). These collaterals had very small diameters (Fig. 7) and it was suspected that blood 
flow may be from normal capillary beds (i.e. oxygenated rather than shunted blood). This 
was consistent with maintenance of improved oxygen saturations, which were available for 
three of five of these patients. In one patient (focal #13), a missed accessory was also 
observed with small collaterals; this was less than 3 mm in diameter and deemed too small 
for embolization; the PAVM will be reassessed in future follow-up. Surgery was not 
performed for any reperfused PAVMs. 
Of the remaining cases that underwent repeat TCE, all re-embolized PAVMs were 
documented as having involuted, although follow-up was not yet obtained m focal patients 
#7 and 22 who recently underwent repeat TCE. 
C. Clinical Follow-Up: 
There were six deaths during the follow-up period, three of which were related to 
HHT. In the focal group (Table 6), patient #1 died five months after her last TCE session 
from a GI bleed; intestinal ulcers unrelated to HHT were found at autopsy (patient did not 
have HHT per Curacao criteria). Focal patient #9 died from injuries sustained during a 
motor vehicle accident. In the diffuse group (Table 7), patient #1 died intra-operatively 
during lung transplantation. Diffuse patient #2, who was 17 years old with HHT at time of 
her first TCE, died over 15 years later secondary to sequelae of liver AVMs. Diffuse patient 
#3, who had HHT, died from a cerebral abscess. Diffuse patient #9 died from pneumonia 
complicated by pneumothorax unrelated to HHT. 
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One neurologic complication (cerebral abscess) occurred during the follow-up period 
in diffuse patient #3. This patient had a history of a prior episode of cerebral abscess that 
prompted referral for TCE of PAVMs. No hemorrhagic complications occurred during the 
follow-up period. 
Prior to her first session of TCE, focal patient #2 was wheelchair-bound secondary 
to hypertrophic osteoarthropathy. The morning after her first session, the patient was able to 
walk and eventually achieved full mobility. 
Of focally-affected patients that had reperfused PAVMs, oxygen saturation was 
available immediately after first attempted TCE of an AVM and pre- and post-repeat TCE in 
12/20 (60%) repeat sessions (Table 9). Comparing sO, between post-first session of TCE 
and pre-repeat TCE, there was a mean drop of 3.6 percentage points (96.8% vs. 93.2%, 
respectively; SD = 4.6%), with p < 0.03. After repeat TCE, the mean rise in s02 over pre¬ 
repeat TCE was 4.6 percentage points (SD = 4.6%), with p < 0.01. Data for comparison in 
the diffuse group was available for only one of three repeat sessions, with the drop in diffuse 
patient #5 from post-original TCE to pre-repeat TCE of one percentage pomt; rise after 
repeat TCE was two points. 
D. Complications of TCE (Table 10): 
Self-limited pleurisy was the most common complication occurring in 18/76 (24%) 
sessions and affecting 14/42 (33%) patients. Pleurisy occurred in 21% of 67 sessions in 
which only focal AVMs were embolized, versus 44% of nine sessions of regional 
embolization; although not statistically significant (p = 0.25), a trend towards increased 
pleurisy in regional embolization was evident. Deployment complications were rare, with 
two instances of coil misplacement (3% of TCE sessions) occurring in 2/42 (5%) patients; 
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both instances occurred without sequelae while embolizing feeding arteries in focally- 
affected patients. The remaining complications each occurred in one patient (1% TCE 
sessions and 2% patients): transient intra-procedural angina, transient intra-procedural leg 
pain, transient brachial plexus injury secondary to prolonged abduction of right arm during 
lateral fluoroscopy, and severe peri-oral pain secondary to the use of glue instead of coil or 
balloon embolic agents. Glue was not used at any other session in this series. Except for 
post-traumatic stress disorder secondary to the use of glue in this patient, there were no 
long-term complications. 
Discussion 
Pulmonary arteriovenous malformations are thin-walled, direct pulmonary artery-to- 
pulmonary vein communications that result in a right-to-left extracardiac shunt. Treatment 
goals are three-fold: (1) prevention of paradoxical neurologic embolization, (2) prevention of 
lung hemorrhage manifesting as massive hemoptysis or hemothorax, and (3) improvement 
of dyspnea/exercise intolerance. 
The clinical manifestations and management of PAVMs have been well-described in 
adults. With ongoing screening of families for HHT and the availability of a clinical DNA 
test, increasing numbers of children and adolescents with PAVMs will be identified. 
Management strategies for PAVMs used in adults have not been carefully evaluated in 
children with long-term follow-up. This study represents the largest series of patients with 
PAVMs aged 18 years or younger undergoing treatment with transcatheter embolotherapy. 
Based on this series and on an extensive review of the English-language literature, it is clear 
that children with PAVMs can have hfe-threatening and debilitating complications, yet may 
be treated efficaciously and safely with TCE. 
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Signs and Symptoms of Pediatric PA VMs 
The classical description of a patient with PAVMs includes cyanosis, clubbing, and 
dyspnea/exercise intolerance. Of 130 children reported in the literature with PAVMs, 75% 
had cyanosis. Slightly more than half of reported children demonstrated dyspnea/exercise 
intolerance and/or clubbing. Of the 42 children in the present series consecutively treated 
with TCE, 60% had cyanosis, 57% had dyspnea/exercise intolerance, and 45% had clubbing. 
In a Mayo Clinic series of 93 patients with a mean age of 40 years, the distribution was 57% 
with dyspnea, 29% with cyanosis, and 19% with clubbing (3). 
Although at first glance it may appear that the classical description of PAVMs 
appears with greater frequency in children, several factors need to be considered. The higher- 
prevalence of cyanosis in children reported in the literature may be the result of reporting 
bias of more severely affected children. Second, of the 42 children presented in this study, 
85% had definite and another 5% had suspected HHT according to the Curacao criteria (35), 
versus 56% definite HHT in the Mayo Clinic series which had consisted mostly of adults. 
Because HHT is associated with bleeding complications (e.g., epistaxis), the present series of 
children is expected to develop a lower rate of secondary polycythemia in response to 
hypoxemia than in the Mayo Clinic series. The presence or absence of polycythemia m 
children was not recorded in this study. Epistaxis was, however, reported as affecting 49% of 
patients in the Mayo Clinic series as compared to 86% of children in the present series. In 
addition, HHT is associated with multiplicity of PAVMs, which may increase the right-to-left 
shunt and hence, increase the likelihood of cyanosis. 
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Neurologic Complications of Pediatric PAVMs 
As described previously, approximately 40% of adults with PAVMs suffer neurologic 
complications such as transient ischemic attack, stroke, and cerebral abscess (4, 6). Only 10% 
of children reported in the literature suffered a clinical neurologic complication related to 
PAVMs: 4% had TIA or stroke and another 5% had cerebral abscess. In the present series 
of children, 5% of children suffered a cerebral abscess and 2% suffered a transient ischemic 
attack. About 18%, however, had evidence of cerebral infarct on MR imaging. Aldiough 
“silent infarcts” are subclinical, it is possible that such infarcts may mcrease in number 
and/or vascular territory affected, resulting in progressive neurologic dysfunction if PAVMs 
remain untreated. 
That the rate of neurologic complications is less than in adults may reflect several 
factors. First, there may be a quantifiable risk per annum for a neurologic event related to 
the presence of a PAVM, i.e., the longer a patient has a PAVM, the greater the accumulated 
risk for experiencmg an adverse neurologic event. This “risk per annum” could increase with 
time as untreated PAVMs grow. Such a risk may explain a higher rate of neurologic events in 
adults who may have had PAVMs for a longer period. Another factor may be that clot 
formation, particularly in lower extremity and pelvic veins, occurs more frequently in adults 
than in children. Thus, adults may be more likely to produce the actual embolus that 
paradoxically enters the cerebral circulation. 
Five percent of children reported in the literature as well as m this series experienced 
a cerebral abscess. Cerebral abscess has a mortality of up to 24% (63, 145-148). Patients with 
a history of PAVMs, particularly if secondary to HHT, are advised to undergo antibiotic 
prophylaxis prior to bacteremic procedures. The risk of cerebral abscess is not eliminated 
when a PAVM is embolized or surgically removed. A sensitive screening test such as 
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contrast echocardiography may indicate the presence of AVMs even in the context of a 
negative pulmonary angiogram; this may be explained by “microAVMs” that, although too 
small to allow clinically significant emboli into the systemic circulation, nevertheless are open 
conduits for bacteria to seed the cerebral circulation. It has been suggested, however, that 
seeding of bacteria is more likely to occur in areas of encephalomalacia, which in turn may 
be caused by previous microemboli, hypoxia, or polycythemic sludging (63, 149). If this is 
the case, then treatment of children and adults with feeding arteries large enough to permit 
passage of emboli, including those who have “silent infarcts” on imaging, could very well 
reduce the risk of cerebral abscess. 
The presence of cyanosis, clubbing, or dyspnea does not seem to reliably predict the 
risk of neurologic complication of PAVMs. However, a trend towards increased risk of 
neurologic complications in cyanotic patients was evident (28% vs. 5.9%, p = 0.16). It can be 
hypothesized that cyanotic patients would more likely have a greater right-to-left shunt and 
hence, higher risk of paradoxical embolization. As many of these patients have HHT with 
bleeding manifestations, the variable degree of secondary polycythemia as compensation for 
chronic hypoxia (and consequent reduction of cyanosis) reduces the predictive power of 
cyanosis for increased risk of neurologic complications. Nevertheless, the presence of 
cyanosis (as well as an oxygen saturation of less than 97%) should raise the suspicion of a 
right-to-left shunt and prompt evaluation with contrast echocardiography. 
Hemorrhagic Complications of Pediatric PAVMs 
Hemoptysis secondary to PAVMs in the adult population has been characterized 
previously (4, 5). In one series of 11 patients with PAVMs who were hospitalized for 
massive hemoptysis or hemothorax, one died and another underwent emergent caesarean 
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section (5). These hemorrhagic events are facilitated by the thm-walls of PAVMs, and it is 
possible that thinning may progress as a PAVM enlarges spontaneously or under the 
influence of the hemodynamic and hormonal changes of pregnancy (5). 
Approximately ten percent of children reported in the literature experienced 
pulmonary hemorrhage secondary to PAVM rupture. This mamfested as minor or massive 
hemoptysis and hemothorax. 
Hemorrhagic complications of PAVMs in children have not previously been 
summarized. Of 14 reported children with hemoptysis or hemothorax in the literature, eight 
had massive hemoptysis. Interestingly, there appears to be a significant mortality associated 
with massive hemoptysis in children (Table 2): five of eight children died after presenting 
with massive hemoptysis. Three of these five children died soon after presenting: two within 
24 hours and one within one week (5). It is interesting to note that the boy who died one 
week after presenting with massive hemoptysis was discharged and was awaiting elective 
embolotherapy. Tins would suggest that because there is significant mortality associated with 
massive hemoptysis in these children, and furthermore, an apparent rapidity of mortality, 
immediate treatment of PAVMs on an emergency basis ought to be seriously considered. 
Only three children in the present series suffered hemoptysis, which was minor in all 
cases. The higher rate of significant hemoptysis in the literature may reflect reporting bias of 
more severe cases. In addition to hemoptysis, two of three children reported with 
hemothorax subsequently died. 
Because a majority of PAVMs are found in patients with HHT, other manifestations 
of HHT may account for hemoptysis. Such pseudohemoptysis may result from significant 
epistaxis or from bleeding tracheobronchial telangiectases. Thus, children suspected of 

PAVM rupture-induced hemoptysis may benefit from ENT examination and perhaps 
bronchoscopy to rule-out pseudohemoptysis. 
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The life-threatening nature of hemorrhagic complications of PAVMs is exemplified 
in the case report of the nine-year old Irish girl with HHT described earlier. This girl 
experienced multiple episodes of hemoptysis requiring four hospitalizations, but eventually 
succumbed to a major episode two weeks before a scheduled appointment with an HHT 
specialist. During the first hospitalization, the patient was noted to have hypoxemia that was 
not corrected with supplemental oxygen. “Inflammatory changes” on chest radiograph were 
noted in the right upper lobe; it was later determined at autopsy that this was the location of 
the PAVM. The patient had definite HHT per the Curacao criteria (35). 
Pulmonary Hypertension and PH 1 /Ms 
This nine-year old girl was subsequently discovered to have changes of pulmonary 
hypertension on histological examination of pulmonary tissue. In fact, evidence of 
pulmonary hypertension was present prior to her death, manifesting as right ventricular 
hypertrophy on electrocardiography and enlarged pulmonary arteries and increased 
cardiothoracic ratio on chest radiography obtained at the fourth hospital admission. 
The association of pulmonary hypertension, defined as a mean pulmonary arterial 
pressure > 30 mmHg, with PAVMs is not new. Although rare, a primary pulmonary 
hypertension-like syndrome has been observed in patients with HHT (36, 150, 151). Primary 
pulmonary hypertension (PPH) has an incidence of 1-2 cases per million per year, and peaks 
during the third decade of life (152). Approximately six percent of people with PPH have a 
family history of the condition, which exhibits autosomal dominant inheritance (152). 
Untreated patients have a median survival of less than three years after diagnosis (153). A 
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gene known as bone morphogenetic protein receptor II (BMPR2) located on chromosome 2 
has been implicated in the inherited form of PPH. BMPR2 is a member of the TGF-(3 family 
of receptors. 
Recently, Trembath and colleagues studied five kindreds and one individual with 
HHT and identified 10 individuals with pulmonary hypertension (36). Molecular analysis 
demonstrated linkage of ALK-1 mutations with HHT and pulmonary hypertension m the 
absence of mutations in BMPR2 or endoglin in all two individuals who also had mutations in 
BMPR2 (both individuals were from the same kindred). Of the eight individuals with 
mutations only in ALK-1, three died as children. In two adults, PAVMs were also found. In 
four individuals, histologic analysis was available and confirmed primary pulmonary 
hypertension-like changes, including occlusive intimal proliferation and plexiform lesions 
(36). 
It is interesting to note that both BMPR2 and ALK-1 are involved in TGF-f3 
signaling. As described previously, the TGF-J3 ligand binds either the type II receptor (such 
as BMPR2) or an accessory protein (such as endoglin) and forms a heteromultimeric 
complex with the type I receptor (ALK-1), with consequent activation of an intracytoplasmic 
phosphorylation cascade that modifies gene expression (36-38). Mutations causing a 
truncation of the BMPR2 protein have been implicated in PPH; similarly, at least two 
families had an ALK-1 variant that would be predicted to lead to a truncated protein. This 
would be consistent with a haploinsufficiency model; however, three families in which ALK- 
1 was implicated in HHT and PPH had amino acid substitutions that would not lead to 
truncation. These mutations may instead have a dominant-negative effect. The nine-year old 
girl with pulmonary hypertension described earlier had an ALK-1 mutation predicted to lead 
to an amino acid substitution without protein truncation. 
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The report of three children dying of a PPH-like syndrome with HHT type 2 (36), as 
well as the case described here, suggests that children undergoing TCE for PAVMs should 
have pulmonary arterial pressures (PAP) measured. None of the 42 children described in the 
present series had an elevated PAP. In the absence of pulmonary hypertension, patients with 
PAVMs tend to have low-normal pulmonary arterial pressures (154). Empirical evidence at 
the Yale Vascular Malformation Center has demonstrated that although embolization of 
PAVMs effectively removes a low-resistance circuit, pulmonary arterial pressures do not rise 
after TCE. This is likely secondary to the presence of microAVMs in E1HT patients that 
absorb the pulmonary blood flow redistributed away from the embohzed PAVMs. It has not 
been reported that unembolized PAVMs grow at a clinically significant greater rate after 
TCE than in patients who have not had TCE. In the presence of PPH, however, the benefits 
of TCE need to be weighed against the possibility of exacerbating an already elevated PAP. 
In such cases, a temporary test occlusion of PAVMs may help to evaluate the effect of 
permanent TCE on pulmonary arterial pressure. 
A ngioarchilecture and Distribution of Pediatric PAVMs 
Because the desired outcome of TCE is involution of the aneurysmal sac, 
consideration of the anatomy of the AVM becomes important. Crucial to successful 
involution is elimination of all feeding arteries to the PAVM (4, 60). Establishing that a 
PAVM is complex helps the interventional radiologist performing TCE know that more 
than one pulmonary segmental artery will need to be selectively catheterized for successful 
TCE of the PAVM. 
Most focal PAVMs in children described in this series were simple (78%) and located 
in the lower lobes (71%), which is similar to the distribution seen in adults (3, 57). A majority 
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of children also had multiple PAVMs (60%), reflecting the high proportion with HHT. As 
noted previously, patients with HHT have a genetic predisposition to developing PAVMs 
throughout their lifetimes; individuals with sporadic PAVMs tend to have a single or few 
congemtal PAVMs (10, 52, 53). Approximately half of the focally-affected children had only 
simple PAVMs while one-third had both simple and complex PAVMs. Of those with diffuse 
PAVMs who had regional lung embolization, 97% of embolized regions were located in the 
lower lobes. The predilection for clinically significant PAVMs to occur m the lower lobes is 
consistent with clinical manifestations of platypnea and orthodeoxia. These clinical 
manifestations, although not documented in the present series, should raise the suspicion of 
PAVMs in a child suspected of having HHT. 
Transcatheter Embolotherapy of Pediatric PA VMs 
In 76 sessions, 174 PAVMs and 35 regions were embolized using predominantly 
stainless steel or platinum coils and/or balloons. Although short-term results after 
embolotherapy may demonstrate improved oxygenation, the primary marker of successful 
long-term outcome of transcatheter embolotherapy is documentation of involution of the 
aneurysmal sac or nidus connecting the pulmonary artery to the pulmonary vein (155). In 
order to document sac involution, imaging follow-up was successfully obtained in 154/174 
focal PAVMs and 22/35 segmental or subsegmental pulmonary arteries. Reasons for 
insufficient follow-up included 1) death prior to scheduled imaging, 2) TCE session near the 
end of the study period with insufficient time for follow-up between TCE and data analysis, 
and 3) failure of patients to respond to requests for follow-up. In three diffuse patients 
without imaging follow-up for three PAVMs and 13 regions (patient #8, 11, and 12), 

oxygenation follow-up was obtained. In all three cases, oxygen saturation remained 
improved. 
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Oxygen saturation prior to intervention was available for 44% of children reported in 
the literature, with a hypoxemic mean s02 of 80.4%. In the present series, mean s02 prior to 
the first session of TCE was 86.7%. Patients with diffuse PAVMs were significantly more 
hypoxemic than patients in the focal group (80.5% vs. 89.4%, respectively). This difference 
makes intuitive sense given the likelihood of a more significant right-to-left shunt in patients 
with diffuse involvement of the lungs. 
Oxygen saturation data measured within 24 hours prior to and after each TCE 
session demonstrated a statistically significant mean rise in sO, immediately after each TCE 
session in both groups. A significant rise in mean s02 was also observed when comparing 
oxygen saturation prior to the first session and after the last session of embolotherapy in 
both groups. However, the improvement in s02 was short-lived in the diffuse group. When 
comparing s02 prior to the first session of TCE and at last follow-up, a significant rise was 
noted in the focal group (although data were available for about half of the focally-affected 
patients), but not in the diffuse group. 
Patients with diffuse PAVMs are more likely to have small or microAVMs compared 
to focally-affected patients. The loss of significantly improved oxygen saturation at long¬ 
term follow-up in the diffuse but not the focal group likely reflects the higher AVM load in 
diffuse patients. It makes intuitive sense that the growth of individual lesions and/or 
increased number of lesions in this population would lead to a rise in the right-to-left shunt, 
and consequently, worsening of hypoxemia. 
In adults, reperfusion occurs in 10-15% of embolized PAVMs (56). In the present 
pediatric series, there was reperfusion of 15% of PAVMs and 0% of regions embolized in 
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45% of patients. Sixty percent of reperfused PAVMs in focally-affected patients and 75% in 
diffusely-affected patients were secondary to recanalization. Hence, recanalization is a major 
culprit m preventing successful outcome of TCE. Although the use of coils versus balloons 
was not recorded for each PAVM embolized, blood flow through coils as well as balloon 
deflation were observed in cases of recanalization, as in adults (56). 
Both coils and balloons are believed to be equally effective in adults (56, 60). The 
advantage of detachable balloons to the interventional radiologist is the ability to achieve 
immediate cross-sectional occlusion with the inflation of one balloon, compared to the 
additional time and contrast media required when placing multiple coils in a feeding artery to 
achieve the same effect. Deflation of detachable balloons has been observed, and is believed 
to be unimportant if the balloon remains inflated for at least 21 days. In this period, effective 
thrombosis has taken place, obviating the need for the balloon to remain inflated (4, 60). 
The use of detachable balloons in the present series was under an FDA investigational 
device exemption. Due to financial considerations, manufacturers of detachable balloons 
have not pursed FDA approval for use of these balloons in PAVMs. As a result, all centers 
participating in this study are now using stainless steel or platinum coils. It is hoped that 
recent advancements in the techniques of coil placement (e.g., anchoring portions of coils in 
proximal branches for security and creating nests of coils to simulate the cross-sectional 
occlusion achieved with a balloon), will help to reduce the rate of reperfusion. 
Missed accessory vessels underlying reperfusion was attributed to lack of a 
pulmonary angiogram after embolization of additional feeding arteries that were believed to 
be too small for embolization. Because there may be multiple feeders to a PAVM, some of 
which may not opacify well on angiography until those that do opacify well are embolized, a 
completion angiogram is now standard practice, as long as contrast media limits have not 
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been reached. If a completion angiogram cannot be performed, CT follow-up to document 
AVM sac/nidus involution becomes even more imperative. 
Although persistence of the aneursymal sac secondary to recanalization or missed 
accessories has been described in adults (56), collateral perfusion (CP) is a new mechanism 
of persistence of the venous sac on CT follow-up described here. CP refers to the 
development of tiny, less than 1 mm diameter vessels to the venous sac of an embolized 
PAVM. The vessels are too small for embolization by coils or balloons, although embolizing 
the distal portion of the pulmonary artery giving off the vessels was performed in several 
children in this series. These collateral do not appear to worsen hypoxemia or increase the 
risk of neurologic complications in patients. The lack of a worsening clinical picture, coupled 
with the small size of the vessels suggests that these collateral vessels may in fact carry 
oxygenated blood to the venous sac. That there was no CP in die diffuse group suggests that 
diffuse involvement of lung surrounding focal PAVMs may inhibit development of 
collaterals from surrounding vessels. 
The majority of the children with CP of PAVMs were not retreated. Of those 
children not retreated, the longest period of follow-up was seven years (focal patient #13). 
The higher prevalence of CP in children versus adults may be related to lung growth. Indeed, 
empirical evidence at the centers participating in this study suggests faster growth of 
untreated PAVMs in children, especially during adolescence. This empirically observed 
higher rate underlies the more frequent imaging follow-up of children versus adults 
undertaken in these centers (six to twelve months after each TCE session, and then every 
three years thereafter versus every five years in adults). 
Reperfusion of PAVMs appeared to cause a statistically significant drop in oxygen 
saturation in the focal group (a reduction of 3.6 percent points). Yet, oxygen saturation 
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measurements with pulse oximetry are poorly reproducible (i.e., have relatively low 
precision). Hence, a mean difference of less than four points is unlikely to be clinically 
significant. Partial pressure of arterial oxygen measurements would be more reliable; 
however, many children were reluctant to undergo multiple arterial sticks that would be 
required. More clinic ally-relevant measures would mclude severity of dyspnea/exercise 
intolerance in the follow-up period. Although worsening of dyspnea/exercise intolerance 
during the follow-up period was not recorded in this study, there was only one neurologic 
complication in the follow-up period (diffuse patient #3). As discussed earlier, embolization 
of pulmonary AVMs does not eliminate the risk of cerebral abscess—as long as a right-to- 
left shunt exists, patients who experience bacteremic events are at risk. The predisposing 
event in this patient resulting in a cerebral abscess was not identified, although the need for 
antibiotic prophylaxis prior to bacteremic procedures was known to him and his parents. 
Although pulse oximetry is imprecise, a significant decrease in sO, did prompt repeat 
TCE, which was successful in achieving AVM involution in all instances in which imaging 
follow-up was obtained. The average rise in mean s02 after repeat TCE was greater than 
four points. In many instances, reperfused PAVMs were retreated along with embolization 
of new PAVMs in the same session. 
Diffuse PAVMs in the Pediatric Setting 
In the largest reported series of patients with diffuse PAVMs, Faughnan et al. studied 
the natural history and management of 16 diffusely-affected patients without 
hepatopulmonary syndrome (63). A higher prevalence of neurologic complications, 
approximately 70%, was found at presentation, which was significantly greater than reported 
for patients with discrete PAVMs (approximately 40%). Among these diffusely-affected 
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patients, 38% experienced a cerebral abscess versus 9% reported in the literature for discrete 
PAVMs; at least half of the diffuse patients were reported as recently visiting a dentist prior 
to development of an abscess (4, 63). 
Although embolization of focal PAVMs in that series did not improve the significant 
hypoxemia in these patients, pulmonary flow redistribution (PFR) did produce a small but 
statistically significant rise in partial pressure of arterial oxygen. In those patients with only 
unilateral diffuse disease, the rise was much more significant. PFR involved temporary 
occlusion of lobar arteries; if partial pressure of arterial oxygen increased by at least 10 
mmHg, a permanent occlusion of lobar circulation was performed. 
In the present series, 12 children with diffuse PAVMs underwent TCE of focal 
PAVMs and/or regional embolization. Four of the 12 children were reported in the series by 
Faughnan et al. (63); two of these four underwent PFR (patients #2 and 3) and both had 
bilateral disease. Of the twelve patients, one had a TIA and one had evidence of a silent 
infarct on MRI. Two developed cerebral abscess, one of whom died after a second episode 
m the follow-up period (patient #3). Two had minor episodes of hemoptysis. Both patients 
who underwent PFR experienced a rise in oxygen saturation, without a real difference in 
dyspnea/exercise intolerance. In one patient (#6), lung transplantation was undertaken at an 
outside institution; that patient died while on post-operative extracorpeal membrane 
oxygenation. 
TCE of discrete PAVMs in diffusely-affected patients appeared to be effective in 
preventing clinical cerebral infarcts although as expected, it did not completely eliminate the 
occurrence of one cerebral abscess. As previously mentioned, mean oxygenation at last 
follow-up was not significantly different from sO, prior to the first session of TCE. It is 
important to note that TCE of discrete PAVMs was performed m these patients to reduce 
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the risk of paradoxical neurologic embolization; improvement of hypoxemia was a secondary 
goal. PFR, however, was performed in order to help reverse the significant hypoxemia in 
these patients and was effective in raising oxygen saturation. As reported by Faughnan et al. 
(63), PFR can produce a statistically significant rise in s02 in patients with diffuse PAVMs; 
however, in most patients, there was little or no improvement m dyspnea despite a rise in 
partial pressure of arterial oxygen (63). 
Based on data from the present series as well as that of Faughnan et al (63), several 
principles of management of children with diffuse PAVMs may be derived. First, discrete 
PAVMs with feeding arteries of at least 3 mm in diameter should be embolized in order to 
reduce the risk of paradoxical neurologic embolization. TCE should be followed-up with CT 
at 6-12 months to document involution of the PAVM. Second, in patients with significant 
dyspnea/exercise intolerance secondary to severe hypoxemia, pulmonary flow redistribution 
may be attempted, although these patients do not seem to experience much symptomatic 
improvement. A subset of these patients—those with unilateral disease—may be better 
candidates for PFR. Third, all patients should undergo antibiotic prophylaxis for bacteremic 
procedures, as in patients with only focal PAVMs. In all patients undergoing angiography for 
diagnostic or therapeutic purposes, pulmonary arterial pressures should be measured to 
exclude the presence of the pulmonary hypertension-variant of HHT (36). 
It has been suggested in the literature that diffuse PAVMs may be an indication for 
lung transplantation (125). In fact, lung transplantation in such patients has been reported 
(156). However, the transplantation-associated morbidity is likely to be worse than 
complications secondary to PAVMs. Faughnan et al, for instance, reported a two-year 
survival of 91% in their series, versus 63% reported for lung transplantation (31, 157). In the 
present series, only one of the 12 patients with diffuse disease died from causes directly 
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related to the presence of PAVMs (cerebral abscess in patient #3). Indeed, diffuse patients 
appear to acclimate well to their hypoxemia—in the Faughnan et al. series, the 
unemployment rate was less than half of that of the general population; all eight patients in 
the current series who were alive had an oxygen saturation between 80-96% at last follow¬ 
up, which is unlikely to produce severely limiting dyspnea or exercise intolerance in the 
setting of compensatory mechanisms for chronic hypoxia (e.g., increased cardiac output, 
polycythemia). One group reported offermg three patients (one male, two female) the option 
to undergo lung transplantation (158). All three refused and have remained stable with 
follow-up of 8-13 years; one woman subsequently had three successful pregnancies (158). 
Therefore, lung transplantation may not yet be as viable a treatment option as might have 
been thought initially. 
Pregnancy and PAVMs 
Although the majority of pregnancies will be in women older than 18 years of age, it 
is conceivable that patients less than 18 years old with PAVMs may become pregnant. 
Several series of women with maternal complications of PAVMs have been reported (64, 
159). Of 161 pregnancies in 47 women with HHT followed at the Hammersmith Hospital in 
the United Kingdom, one maternal CVA occurred out of 138 pregnancies in women without 
any evidence of PAVM for at least two years postpartum, versus six cases of deterioration of 
pulmonary shunt, two cases of fatal pulmonary hemorrhage, and two cases of maternal CVA 
mil women with PAVMs who had 23 pregnancies (159). The difference in the number of 
maternal complications was statistically significant (p < 0.01), although there was no 




Hemodynamic changes of pregnancy may explain the increased risk of complications 
from PAVMs during pregnancy. There is a rise m cardiac output of up to 40% at term. With 
increased vascular volume, there is usually an accompanying fall in systemic and pulmonary 
vascular resistance. In the setting of abnormal and fragile AVMs, one may expect a higher 
incidence of hemorrhage with the increased vascular volume; there may also be a higher risk 
of a paradoxical stroke as PAVMs dilate (159). These hemodynamic changes also appear to 
affect malformations in other vascular beds, including the liver (160) and brain (161), with 
the latter resulting in intracranial hematomas (161). In addition, circulating estrogens and 
progesterone may result in increased venous distensibility, and consequently PAVM dilation, 
with elevated risk of hemorrhage and paradoxical stroke (14, 15). 
Gershon et al. reviewed 26 case reports of women suffermg complications of 
PAVMs during pregnancy (64). Sixty-one perent had known HHT. Twelve percent of 
women described died (two from pulmonary hemorrhage, one from stroke), 50% had 
hemothorax, 26% had hemoptysis, 4% had worsening shunt, and 8% suffered a stroke (64). 
In 85%, complications occurred during the latter two trimesters. Gershon et al. undertook a 
prospective study of seven women (age 24 — 34 years) with a total of thirteen PAVMs who 
underwent transcatheter embolotherapy while pregnant. All seven had TCE during their 
second or third trimester (gestational age 16-36 weeks). All deliveries were uneventful, 
occurred vaginally, and all infants were well at one year of age. There were no maternal 
complications of PAVMs post-TCE. Modified TCE was undertaken in order to reduce fetal 
radiation exposure. Because lead aprons do not prevent intra-thoracic scatter of radiation, 
other modifications were performed, including use of collimation, minimization of 
fluoroscopy, and use of digital subtraction angiography. Fetal radiation dose was measured in 
all cases and ranged from 50 to 220 mrad. The fetal radiation exposure was considered 

41 
minimal, and was excellent compared to established maximum radiation limits of 500 mrad 
for pregnant workers (64). 
Because of the high rate of morbidity, it is imperative that patients with HHT who 
become pregnant be screened for PAVMs. Ideally, PAVMs should be treated prior to 
conception. In the case of a pregnant patient with PAVMs, it appears TCE is safe and 
effective, but should be undertaken durmg the second or third trimester in order to avoid 
radiation exposure during organogenesis in the first trimester. TCE during pregnancy should 
be performed with modifications that reduce radiation exposure to the fetus, in particular, 
appropriate collimation of radiation and mmiinization of fluoroscopy. 
Manifestations of HHT in Children with PM VMs 
As important as it is to screen children of HHT families for PAVMs, it is also 
important to screen children with PAVMs for HHT. A majority of children in this series had 
clinical evidence of HHT. In addition, family members of children with PAVMs will also 
need to be screened for HHT, and if positive, for PAVMs. 
Morbidity and mortality in children with HHT is not manifested only by pulmonary 
arteriovenous malformations. Cerebrovascular malformations (CVMs) are an important and 
significant source of morbidity and mortality in patients with HHT. CVMs are relatively 
silent until spontaneous hemorrhage occurs, which may be a devastating first symptom (13, 
48, 162). Easey et al., based on over 22,000 HHT patient-years, found that men and women 
with HHT aged 45 years or less were 20 and six times more likely, respectively, than the 
general population to experience a cerebral hemorrhage (49). Using digital subtraction 
angiography, Willemse et al. found a CVM prevalence rate of 12% in consecutively screened 
HHT patients (48). Using non-contrast and gadolinium-enhanced MRI, Fulbright et al. 
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found the prevalence rate to be 22% (13); the latter rate was likely higher due to increased 
detection of microAVMs and cerebral telangiectases. When considering CVMs larger than 
10 mm in diameter, the prevalence rates in the two studies were 12% and 11%, respectively. 
Maher et al., however, found a prevalence rate of only 3.7% (163); yet, only 46 of 321 
patients were screened by MRI, as a study protocol was used in which only symptomatic 
patients were screened. If the prevalence rate was 10%, it would be expected diat 32/321 
patients m diat series would have a CVM at least 10 mm m diameter detectable by MRI 
(164). 
A macro-CVM prevalence rate of at least 10%, combined with a risk of cerebral 
hemorrhage of 1.4-2.0% per annum for HHT CVMs (49), would argue for screening for 
CVMs in all patients with HHT, with one brain MRI. Although the studies just described 
overwhelmingly involved adult populations, screening of children is also imperative. If 
CVMs are presumed to be congenital, than the previously quoted prevalence rates would 
also apply to children. Significant morbidity and mortality from cerebral hemorrhage m 
children with HHT was recently reported by Morgan et al (165). In their series of nine 
children (aged 0-16 years) with intracranial hemorrhage and a family history of HHT, all nine 
were demonstrated to have a CVM on autopsy, imaging, or surgery. Six of the nine families 
were tested for linkage to the endoglin mutation for HHT type 1; in all six, linkage was 
present. In the three children not tested, HHT was diagnosed in family members using the 
Curacao criteria (35). There were no clinical indications of CVM prior to ICH. Outcomes of 
ICH included death in five, significant cognitive and motor impairment in three, and 
hemiparesis in one child. As their experience demonstrates, cerebrovascular malformations 
occur in children with HHT and may carry significant morbid and fatal consequences. 
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In the present series, five of 34 children screened with cerebral imaging had a CVM. 
Two of these five were subsequendy treated with surgery. Of the remaining eight children 
not screened, two developed an intracranial hemorrhage, one with unresolved hemiparesis 
and another who has fully recovered. Thus, at least four children in this series had a CVM 
that had or should have had treatment. None of the children widr an unruptured CVM had 
neurologic symptoms attributable to it. These data support the need for screening of all 
children with HHT for CVM. Children in HHT families who may have no manifestation of 
HHT nevertheless should be screened for CVMs with a brain MRI, just as they should be 
screened for PAVMs using contrast echocardiography, as other manifestations of HHT may 
have delayed penetrance. This should be particularly acceptable given the significant 
morbidity and mortality of both types of AVMs and the relatively benign nature of the 
screening modalities. The development of CVMs in HHT patients after a negative brain 
MRI has not been reported; the current recommendation is to screen only once (164). 
The most common manifestation of HHT in all age groups is epistaxis. 
Unfortunately, because nosebleeds are often presumed to be “normal” unless severe, 
pediatricians would be expected to have a low clinical suspicion of HHT simply based on 
this criterion. The appearance of epistaxis is not a predictor of the presence of PAVMs (46). 
There are several management strategies for severe epistaxis, including laser cautery and 
septal dermoplasty (166), although severe epistaxis requiring such treatments is uncommon 
in children. As another common manifestation of HHT, cutaneous telangiectases typically 
appear in the second or third decade of life, and usually increase in number with age. Such 
telangiectases appeared in nearly 80% of children in this series. Physicians examining 
children with epistaxis should search for telangiectases as their identification is straight¬ 
forward and their presence would significandy raise the suspicion of HHT. 
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Less than two percent of HHT patients with GI involvement manifest this 
involvement prior to 30 years of age (40). GI manifestations are the initial presentation of 
HHT in less than one percent of HHT patients (40). Typical endoscopic findings include 
multiple small, red, well-defined flat nodules with stellate projections and an “anemic halo” 
(167) . Bleeding from colonic telangiectases has been reported in four children aged 1-5 years 
(168) . Gastric involvement and hematemesis was described in one 10-month old infant (169) 
and in a one-year old, GI bleeding occurred with hepatobiliary vascular anomalies (170). A 
14-year-old girl with a positive family history of HHT was also reported as having persistent 
bright red blood per rectum, despite negative findings on colonoscopy, esophagastro- 
duodenoscopy, and intraoperative endoscopy; subsequently, typical lesions were found on 
pathologic examination of a specimen after a right-sided ileocolectomy (40). In another 
report, an 8-year old boy with a positive family history of HHT presented with significant 
abdominal distention lasting five years; laparotomy demonstrated a 6-10 cm segment of 
dilated jejunum, with a fibrous constriction at on end (171). Histopathologic examination 
demonstrated hemosiderin granules and thin, dilated post-capillary venules (171). 
Interestingly, rare cases of children with HHT and juvenile polyposis have been 
reported (89, 129, 172, 173). Juvenile polyps are benign neoplastic protrusions often 
hamartomatous in nature and found in the colorectum of children. When such polyps are 
multiple and hereditary, the condition is known as juvenile polyposis coll (173-175). 
Although juvenile polyposis coll is not considered to be premalignant, patients with 
generalized juvenile polyposis of the GI tract appear to have a higher incidence of 
gastrointestinal carcinoma, as reported in at least one kindred (89, 176). A mutation in the 
protein tyrosine phosphatase gene on chromosome lOq has been implicated (177). However, 
a common genetic mutation that could explain the co-occurrence of juvenile polyposis and 
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HHT has not been found, although it has been suggested that one likely exists given the 
improbability of two rare disorders appearmg in the same family (89, 129, 172, 173). In the 
present series, focal patient #2 has juvenile polyposis coll without significant hematochezia. 
Interestingly, this patient was wheelchair bound prior to TCE, secondary to hypertrophic 
osteoarthropathy. There are at least two case reports of children with HHT, juvenile 
polyposis, and hypertrophic osteoarthropathy (72, 78). Although the pathogenesis of 
hypertrophic osteoarthropathy is poorly understood, it seems to be directly related to the 
pulmonary vascular shunt, as the patient achieved normal mobility after TCE. 
Thus, it appears that children with HHT may rarely manifest with gastrointestinal 
signs and/or symptoms from bowel telangiectases, juvenile polyps, or strictures. Because 
telangiectases may occur anywhere in the GI tract, colonoscopy and esophagastro- 
duodenoscopy may be normal; in such cases, capsule endoscopy may be warranted. GI 
bleeding secondary to telangiectases may vary in severity, and response to treatment, 
including drug (ethinyl estradiol/norethindrone, danazol, aminocaproic acid) or endoscopic 
therapy, may be excellent in some patients (16, 167). 
In the present series, one girl presented with PAVMs at age 17; over 15 years later, 
she died of liver AVMs (LAVMs). Symptomatic liver AVMs have rarely been reported in 
children with HHT (77). In one reported child, liver involvement was suspected when 
esophageal varices were detected on a barium study (77). The patient demonstrated 
thrombocytopenia, and subsequently had a splenectomy; no cirrhosis was found on liver 
biopsy despite dilated vascular channels and portal hypertension. In three other children 
reported in the literature (45, 109, 131), liver AVMs were found incidentally. Portal-to- 
hepatic vein, hepatic artery-to-portal vein, and hepatic artery-to-hepatic vein shunting have 
been observed angiographically (14, 15). Symptomatic LAVMs usually occur later in life, 
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with a median age of 55 years in one series of 19 patients (14), and may produce three 
clinical syndromes with some overlap: high-output cardiac failure, portal hypertension, and 
biliary disease. The risk of high-output cardiac failure is higher in patients with significant 
hepatic artery-to-hepatic vein shunting (14). Portal hypertension may be secondary to hepatic 
artery-to-portal vein shunting, while biliary disease akin to Caroli’s disease may be secondary 
to hypoperfusion of the peribiliary plexus resulting from the development of AV shunts (14, 
15). 
Recently, Ianora et al. screened 70 consecutive patients diagnosed or suspected of 
having HHT for LAVMs with multiphasic multi-detector row helical CT (178, 179). Fifty- 
two patients (74%) demonstrated hepatic vascular anomalies: of these 52, 8% were 
symptomatic, 52% had arterioportal shunts, 15% had arteriosystemic shunts, 33% had both 
shunt types, and 0% had portosystemic shunts. In addition, of these 52 patients, 63% had 
hepatic telangiectases, 25% had large confluent hepatic vascular masses, and 60% had 
indirect CT signs of portal hypertension of which only one patient had clinical signs. The 
high rate of asymptomatic hepatic vascular anomalies and lack of efficacious management 
strategies for symptomatic LA VMs that are unlikely to manifest in children argue against 
screening children for liver HHT. 
Conclusion 
Untreated pulmonary arteriovenous malformations are associated with significant 
morbidity and mortality in children as in adults. The present series establishes the safety and 
efficacy of transcatheter embolotherapy in the pediatric population. Although no neonates 
were treated with TCE in this series, reports of embolization of PA VMs in infants less than 
a year of age have demonstrated good results (67). 

47 
The primary indication for embolization of PAVMs with a feeding artery diameter of 
at least 3 mm is to reduce the risk of paradoxical neurologic embolization. Embolization of 
PAVMs effectively prevents life-threatening massive hemoptysis and hemothorax and may 
also be performed as emergent treatment for such complications. Improvement of 
oxygenation is a secondary goal, particularly in patients who acclimate well clinically to 
hypoxemia. Diffuse patients with severe hypoxemia may require more extensive 
embolization techniques, such as pulmonary flow redistribution, although results have been 
worse in those with bilateral than in those with unilateral disease. Children undergoing 
catheter-based angiography should have pulmonary artery pressures measured to rule-out the 
primary pulmonary hypertension-like variant of HHT. All children with PAVMs should have 
antibiotic prophylaxis prior to bacteremic procedures. 
Approximately one-half of the patients in this series had reperfusion of PAVMs after 
transcatheter embolotherapy. Repeat TCE was successful m achieving involution of all 
reperfused PAVMs in which imaging follow-up was available. Persistence of the aneurysmal 
sac with imaging follow-up should prompt diagnostic angiography, with repeat TCE if 
necessary. Persistence of a venous sac on CT, with demonstration of collateral perfusion on 
angiography, does not warrant repeat TCE. Given the significant reperfusion rate despite the 
extensive experience of the interventional radiologists performing the procedure, patients 
with PAVMs should be referred to “centers of excellence”—institutions with experience m 
the specialized techniques required to bring about successful outcomes. Such centers would 
perform the extensive follow-up required, in conjunction with the family physicians, 
internists, and pediatricians caring for these patients. These centers would have a network of 
HHT specialists who can provide an easily-coordinated, multi-disciplinary approach to the 
care of patients with HHT. 
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Because a majority of children with PAVMs will have HHT, all children discovered 
to have PAVMs should be screened. Those positive for HHT should also be screened with 
brain MRI for CVMs as these vascular malformations are associated with significant 
morbidity and mortality. Screening for HHT should extend beyond the child and involve 
family members. 
A clinical DNA test is now available and it is believed that in the future many more 
patients will be diagnosed with HHT, approximately one-third of whom will have PAVMs. 
As more children are diagnosed, general pediatricians and pediatric pulmonologists and 
cardiologists will be forced to become aware of the potential debilitating and life-threatening 
complications of PAVMs, as well as of the availability of transcatheter embolization as a safe 
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Figure 1. (A) Pulmonary angiogram demonstrating multiple small pulmonary 
arteriovenous malformations in the left lung of focal patient #3 at age 10 
years. Follow-up pulmonary angiogram 8 years later (B) demonstrates 
interim growth of multiple PAVMs (arrows). 

Figure 2. Pulmonary angiogram in diffuse patient #9, demonstrating diffuse 




Figure 3. Pulmonary angiogram in focal patient #24 demonstrating a simple 
pulmonary arteriovenous malformation, with a single pulmonary feeding 
artery (PA), venous sac, and a single draining pulmonary vein (PV). 
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Figure 4. Pulmonary angiogram in focal patient #25, demonstrating a complex 
PAVM. There are multiple feeding arteries derived from at least two 
pulmonary segmental arteries (arrows). The draining pulmonary vein (PV) 
is also visualized. 
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Figure 5. (A) Large PAVM with one feeding pulmonary artery (PA) and one draining 
pulmonary vein (PV) in focal patient #15, occluded (B) with detachable 
balloons (arrows). Follow-up angiography one year post-TCE demonstrates 




Figure 6. Two large feeding arteries (black arrows) to three PAVMs (white arrows) are 
identified (A) in the right lower lobe of focal patient #10. The lateral feeder 
that eventually supplies two of the three PAVMs is embolized (B) with one 
coil (black arrow) distal to one balloon (white arrow). Follow-up at five 
months demonstrates recanalization (C), likely from early balloon deflation 
and insufficient coiling. Repeat TCE (D) with a new balloon (white arrow) 
and substantial distal coiling (black arrow) performed. Successful involution 
was demonstrated on CT and angiography, with seven years follow-up. 
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Figure 7. (A) A simple PAVM is identified in the right lower lobe of focal patient #28. 
A single pulmonary segmental artery (PA) supplies the feeders to the AVM, 
while a single draining pulmonary vein (PV) is identified during the arterial 
phase of the angiogram. Embolization of the artery supplying the feeders (B) 
is performed with a detachable balloon (white arrow) and coils (black arrow). 
At one-year follow-up, incomplete involution is noted on CT scan. 
Subsequent pulmonary angiogram (C) demonstrates collateral perfusion of 




Table 1. Clinical Characteristics of 130 Children with PAYMs Repotted in the Literature 
Signs and Symptoms of PA VlSls 
Number Reported/ 
Total Children Percent 
Dyspnea/ Exercise Intolerance 66/130 51% 
Cyanosis 97/130 75% 
Clubbing 70/130 54% 
Polycythemia 17/130 13% 
Complications of PA VMs 
Transient Ischemic Attack 2/130 2% 
Stroke 3/130 2% 
Cerebral Abscess 7/130 5% 
Hemoptysis 11/128 9% 
Hemothorax 3/130 2% 
Other Clinical Characteristics B 
Epistaxis 17/130 13% 
Cutaneous Telangiectases 32/130 25% 
Headache 3/130 2% 
Cerebrovascular Malformation (CVM) 4/130 3% 
Cerebral Hemorrhage' 1/130 1% 
GI Telangiectases 4/130 3% 
Liver AVM 4/130 3% 
Unidentified Neurologic Event0 6/130 5% 
Family History of HHT or PAVM 29/130 22% 
A • • • 
Polycythemia indicated by explicit report by authors, not based on hemoglobin or hematocrit values. 
BClinical characteristics that were explicitly reported. Many authors did not explicitly state looking for 
these characteristics, e.g., did not perform imaging to exclude CVM or endoscopy for GI telangiectases. 
(2 
Cerebral hemorrhage occurred secondary to rupture of a cerebrovascular malformation. 









Confirmation Hemoptysis Time Course Outcome 
83 1948 8 / M Yes Operation 3-4 episodes / 3 yr Recovered 
131 1955 13 / M N/A Operation 2 episodes / 1 yr Recovered 
134 1956 5/M N/A Operation Multiple episodes / 3 months Died15 
85 1961 18 / M N/A Operation 15-30 episodes / 4 yr Died 
118 1962 13 / M N/A Operation 2 episodes / 3 months Recovered 
113 1988 7 / F Yes Autopsy 1 episode / < 24 hrs Died 
5 1994 15 / M Yes Autopsy 2 episodes / 1 week Died 
144 2001 15 / F Yes Autopsy 1 episode / < 24 hrs Died 
A 
HHT diagnosis based on Curacao criteria (35). 
BChild died during PAVM resection performed after 16 hemoptysis-free days. 
N/A = not enough information to establish diagnosis of HHT. 
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Table 3. Summary of Three Reported Children with Hemothorax and PAVMs 
Reference Year Age/ Gender HHT^ PAVM Confirmation Outcome 
84 1936 0 / M N/A Autopsy Died 
54 1959 16 / M Yes Autopsy Died 
115 1988 0 / M N/A Operation Recovered 
AHHT diagnosis based on Curacao criteria (35). 
N/A — not enough information to establish diagnosis of HHT. 
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Table 4. Oxygenation Parameters for 130 Children with PAYMs Reported in the Literature 
Parameter Number Reported (Percent)A Mean Range 
Oxygen Saturation (pre-procedure) 57/130 (44%) 80.4% 55 - 98 
Arterial Partial Pressure of 02- Room Air 24/130 (19%) 46.2 mmHg 35 - 77 
Arterial Partial Pressure of 02- 100% 02 12/130 (9%) 96.6 mmHg 32 - 344 




Hemoglobin 64/130 (50%) 16.7 g/dl 9.7 - 24 
Hematocrit 
tt,—:--"7—;-:- 
47/130 (36%) 53.8 ml/dl 22 - 79.5 
‘Number of children with data point reported/total children in literature review. 
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Table 5. Clinical Characteristics of 42 Children with Pulmonary Arteriovenous Malformations 
Signs and Symptoms ofPAVMs Focal Diffuse Total 
Dyspnea/Exercise Intolerance 16/30 (53%) 8/12 (67%) 24/42 (57%) 
Cyanosis 13/30 (43%) 12/12 (100%)* 25/42 (60%) 
Clubbing 10/30 (33%) 9/12 (75%)* 19/42 (45%) 
Complications ofPAV'Ms Focal Diffuse Total 
TIA/Stroke 0/30 (0%) 1/12 (8%) 1/42 (2%) 
MRI- Brain InfarctA 4/23 (17%) 2/10 (20%) 6/33 (18%) 
Cerebral Abscess 0/30 (0%) 2/12 (17%)* 2/42 (5%) 
Hemoptysis 1/30 (3%) 2/12 (17%) 3/42 (7%) 
Hemothorax 0/30 (0%) 0/12 (0%) 0/42 (0%) 
Other Manifestations ofHHT Focal Diffuse Total 
Epistaxis 27/30 (90%) 9/12 (75%) 36/42 (86%) 
Cutaneous Telangiectases 23/30 (77%) 10/12 (83%) 33/42 (79%) 
Headache 17/30 (57%) 8/12 (67%) 25/42 (60%) 
Cerebrovascular Malformation15 5/24 (21%) 2/10 (20%) 7/34 (21%) 
Cerebral Hemorrhage 2/30 (7%) 0/12 (0%) 2/42 (5%) 
Liver AVMC 0/30 (0%) 1/12 (8%) 1/42 (2%) 
MRI- Brain Infarct- Brain infarct detected in children who were screened by MRi, eg, Focal: 4/23 = 4 of 23 
children who were screened by MRI were demonstrated to have a brain infarct. 
^Inclusive of patients who had brain MRI and one patient who had brain angiogram. 
CDiffuse patient #1 (Table 7) was symptomatic and subsequently screened for hepatic AVMs; no other 
patient was screened for liver AVMs. 
p < 0.05 for comparison to focal group. 
TXA/Stroke = transient ischemic attack or stroke. 
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Last F/U Reperfusion 
Current 
Status 
1 4 F 1979 LLL S 1 47 N/A 1 N/A 0/1 DiedA 
1980 LLL S 1 44 72 N/A 
2 16 F 1984 LNG S 2 89 98 18 N/A 0/2 Well 
3 10 F 1984 RUL C 1 96 N/A 18 N/A 1/2 Well 
RLL s 1 0/1 
1991 LNG s 2 86 96 0/2 
1992 LLL s 2 84 89 0/2 
RLL s 2 1/2 
1995 RLL s 1 94 96 0/1 
RUL s 1 0/1 
4 17 F 1987 RLL c 1 90 96 15 N/A 1/1 Well 
RML s 1 0/1 
LLL s 1 0/1 
5 11 M 1987 RUL c 1 N/A N/A 17 98 1/1 Well 
6B 8 M 1987 RLL c 1 79 94 15 N/A 1/1 Well 
LLL c 1 1/1 
1994 LLL s 1 85 98 0/1 
2000 RLL s 1 92 97 0/1 
7 11 F 1990C RLL s 1 N/A N/A 12 99 1/1 Well 
LLL s 1 1/1 
8 7 F 1990 RML s 1 85 96 11 98 0/1 Well 
RLL c 1 1/1 
RLL s 1 1/1 
1994 LLL s 1 87 97 0/1 
1998° RML s 2 94 98 0/2 
RLL s 6 0/6 
LLL s 4 0/4 
LNG s 1 0/1 
9b 11 F 1991 RLL s 1 95 99 7 97 0/1 Died* 
LLL s 1 0/1 
1998 LLL c 1 94 97 N/A 
10 16 M 2/92 RLL c 1 85 97 7 98 1/1 Well 
RLL s 2 0/2 
7/92 RLL s 1 83 96 0/1 
1999 RLL c 1 96 98 0/1 
11 12 M 1992 LLL c 1 75 98 10 99 1/1 Well 
12 18 F 1993 RUL c 1 81 92 5 97 0/1 Well 
1994 RLL s 2 92 96 0/2 
LUL s 1 0/1 
13 13 M 1994 LLL c 1 87 96 8 94 1/1 Well 
RLL c 1 1/1 
RLL s 1 0/1 
14 12 M 1995 RLL s 1 N/A 96 7 98 1/1 Well 
2002 RUL s 1 99 98 N/A 
Continued on next page. 
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15 9 M 1996 LLL S 1 83 92 6 98 0/1 Well 
1997 RML C 1 91 98 0/1 
2002 RLL s 1 96 98 N/A N/A 
LNG s 1 N/A 
16 7 M 1996 RLL c 1 94 98 6 N/A 1/1 Well 
17 15 F 1997 RML s 1 94 99 4 99 0/1 Disabled' 
18 18 F 1997 LNG c 1 98 100 5 N/A 0/1 Well 
19 4 M 1998 LLL s 1 95 97 4 97 0/1 Well 
20 15 F 1998 LLL c 1 92 97 G N/A N/A Well 
21 13 M 1998 RLL s 1 95 99 4 100 0/1 Well 
2002 LLL s 2 N/A 100 N/A N/A 
22 12 M 1999 RLL s 1 97 99 3 98 1/1 Well 
2002 RML s 1 96 98 N/A 
23 12 F 1999 RLL s 1 98 100 3 100 0/1 Well 
24 18 F 1999 LLL s 2 97 97 3 N/A 1/2 Well 
25 8 M 1999 RML c 1 87 99 G N/A N/A Well 
26 12 M 2000 LUL c 1 92 98 1 N/A 0/1 Well 
RLL s 1 0/1 
27 17 F 2000 RLL s 1 95 99 G N/A N/A Well 
28 12 M 2000 RLL s 2 91 96 2 95 1/2 Well 
2001 LNG s 1 97 100 0/1 
29 5 F 2000 RLL s 1 97 99 2 98 0/1 Well 
30 12 F 2001 RLL s 1 100 99 1 N/A 0/1 Well 
Child died 5 months after treatment from massive GI bleed- ulcer found on autopsy. 
BPatient had prior embolization at outside institution. 
c 
Patient embolized in 2 sessions over 5 months. 
°Patient embolized in 2 sessions over 2 months. 
1 Died in 1998 from a car accident. 
1 Unresolved right hemiparesis after hemorrhagic stroke due to CAVM rupture. 
Q 
Lost to follow-up. 
Loc = PAVM location; LLL = left lower lobe; LUL = left upper lobe; LNG = lingula; RLL = right lower 
lobe; RML = right middle lobe; RUL = right upper lobe; N/A = not available/applicable; s02 = 02 
saturation (%); Reperfusion = occluded vessel/AVM found on follow-up to be recanalized (RC), to have 
a missed accessory vessel (MA), or to have developed collateral perfusion (CP), see text and Table 9; 
tAVM - total PAVMs with > 3mm feeding artery occluded; Type = PAVM type: S- simple, C- complex, 

















Last F/U Reperfusion 
Current 
Status 
1 6 M 1983 RLL S 4 83 83 10 N/A 0/4 DiedA 
1988 RLL S 2 N/A N/A 0/2 
LLL S 1 0/1 
2 17 F 1984 RLL S 1 84 88 18 85 1/1 Died15 
1985 RLL S 1 N/A 87 0/1 
1991 RLL S 2 84 80 0/2 
LLL S 2 0/2 
1993 RLL Seg 5 80 91 0/5 
RUL S 1 0/1 
3C 15 M 1986 RLL S 2 75 75 16 87 0/2 Died° 
LLL S 4 0/4 
1991E LLL Seg 3 77 85 0/3 
RLL Seg 3 0/3 
RML S 1 0/1 
1998 LNG s 1 92 87 0/1 
RLL s 2 0/2 
4C 15 M 1990 LLL Seg 1 89 91 9F 94 0/1 Well 
1994 LLL Seg 1 89 94 0/1 
1999 LUL C 1 94 94 N/A 
5 15 M 1997° RLL S 1 80 84 6 85 1/1 Well 
1999 LLL S 2 83 88 0/2 
RLL s 4 0/4 
2001 LLL s 2 83 87 0/2 
RLL s 3 0/3 
6 13 F 1997 LLL s 1 86 89 5 67 0/1 Died" 
RLL s 1 0/1 
2000 RLL s 1 80 81 0/1 
7C 16 F 1998 LLL s 6 86 91 5 96 0/6 Well 
LUL s 1 0/1 
RLL s 4 0/4 
RUL s 7 0/7 
19991 RLL s 3 86 97 0/3 
RAIL s 2 0/2 
LLL s 8 0/8 
LUL s 4 0/4 
2001 LLL s 1 95 95 1/1 
RUL s 1 1/1 
2003 RLL s 2 96 96 N/A 
RML s 1 N/A 
RUL s 2 N/A 
8C 7 F 19991 LLL s 2 89 94 2 95 0/2 Well 
LUL s 1 0/1 
RLL s 1 0/1 
2001 RUL s 1 90 95 N/A 
RML s 1 N/A 
LNG s 1 N/A 
Continued on next page. 
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Last F/U Reperfusion 
Current 
Status 
9C 10 F 20001 RUL Seg 1 81 94 2 90 0/1 Well 
RLL Seg 1 0/1 
RLL Pseg 1 0/1 
10C 7 M 2000 RLL Seg 1 84 97 2 93 0/1 Well 
RLL Pseg 2 0/2 
11C 4 F 2001 RLL Seg 3 62 74 1 80 0/3 Well 
2002 LLL Pseg 3 70 77 N/A 
12CK 7 F 2002L RLL Seg 3 67 77 0.5 81 N/A Well 
RLL Pseg 4 N/A 
LLL Pseg 3 N/A 
\ 
Died during lung transplantation. 
BDied in 2002 from liver HHT. 
Q 
Patient had prior embolization at outside institution. 
°Died from second brain abscess. 
p 
Patient embolized in 2 sessions over 4 months. 
FLost to follow-up. 
G 
’Vessels to this RLL AVM embolized in three sessions over 5 months. 
H • 
Patient was DNR after pneuomothorax; multiple comorbidities unrelated to HHT. 
Patient embolized m 2 sessions over 1 month. 
'Patient embolized in 2 sessions within 2 months. 
K • 
Patient had diagnostic angiogram at Yale in 1998. 
LPatient embolized in 2 sessions over 5 months. 
Loc = PAVM location; LLL = left lower lobe; LUL = left upper lobe; LNG = lingula; RLL = right lower 
lobe; RAIL = right middle lobe; RUL = right upper lobe; N/A = not available/applicable; s02 = 02 
saturation (%); Reperfusion = occluded vessel/AVA1 found on follow-up to be recanalized (RC), to have 
a missed accessory vessel (MA), or to have developed collateral perfusion (CP), see text and Table 9; 
tAVM = total PAVMs with > 3mm feeding artery, or segments occluded; Type = PAVM type: S- simple, 
C- complex, Seg- total segment(s) blocked, eg, superior segment of RLL, Pseg-partial segment blocked; 
Lob- lobar artery blocked, see text; Years F/U = follow-up from first occlusion documenting involution 
of PAVM to 2002 or year of death. 
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Table 8. Analysis of Oxygenation Data for 42 Children with Pulmonary Arteriovenous Malformations 
Comparison of sOa Pre- and 
Post-All TCE Sessions 
Comparison of s02 Prior to First 
and After Last TCE 
Comparison of s02 Prior to 
First TCE and at Last F/U 
Pre-First Session Post-Last Pre-First s(J2 at Last 
Pre-TCE s02 Post-TCE s02 s02 Session s02 Session s02 F/U 
FOCAL 
Mean 90.0 96.6 89.4 97 89.9 97.7 
SD 9.4 4.5 10.6 5.2 7.2 1.7 
Range 44 - 100 72- 100 47 - 100 72- 100 75 - 98 94-100 
p-value <0.00001 <0.00001 0.0012 
DIFFUSE 
Mean 83.3 87.8 80.3 88.7 80.3 86.6 
SD 8.2 7.1 8.9 7.5 8.9 8.5 
Range 62-96 74-97 62-89 77 - 97 62-89 67 - 96 
p-value <0.0001 0.0005 0.053 
TOTAL 
Mean 87.4 93.2 86.8 94.6 85.6 92.8 
SD 9.5 7.0 10.9 7.0 9.2 8.0 
Range 44-100 72- 100 47-100 72-100 62 - 89 67 - 100 
p-value <0.00001 <0.00001 <0.0002 
SD - Standard deviation; s02 = Oxygen saturation; TCE = Session of Transcatheter Embolotherapy 
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Date Loc Type 
Reperfusion Type 






sQ2 (%) AVM Status 
FOCAL 
3 2/10 1984 RUL C MA 1991 86 96 Involuted 
1992 RLL S RC, CP 1995 94 96 Involuted 
4 1/3 1987 RLL c MA 1997 96 97 Involuted 
5 1/1 1987 RUL c RC 1991 94 99 Involuted 
6 2/3 1987 RLL c MA 1994 85 98 Involuted 
CP 2000 92 N/A Involuted 
LLL c MA 1994 85 98 Involuted 
MA, CP 2000 92 N/A Involuted 
7 2/2 1990 RLL s RC 1997 96 99 Involuted 
RC 1998 99 100 Involuted 
LLL s RC 1997 96 99 Involuted 
RC 2002 98 99 Awaiting F/U 
8 2/17 1990 RLL s RC, CP 1994 87 97 Involuted 
RC 1998 94 98 Involuted 
RLL c RC 1998 94 98 Involuted 
10 1/5 2/92 RLL c RC 7/92 83 96 Involuted 
CP 1999 96 98 Involuted 
11 1/1 1992 LLL c MA, CP 1994 N/A 96 Involuted 
13 2/3 1994 LLL c CP 1997 93 96 Involuted 
1994 RLL c MA, CP 1997 93 96 Not Treated 
14 1/1 1995 RLL s CP - - - Not Treated 
16 1/1 1996 RLL c CP - - - Not Treated 
22 1/1 1999 RLL s RC 2002 96 98 Awaiting F/U 
24 1/2 1999 LLL s CP - - - Not Treated 
28 1/3 2000 RLL s CP 2001 97 100 Not Treated 
DIFFUSE 
2 1/11 1984 RLL s MA 1985 N/A 56/87 Involuted 
5 1/12 1997 RLL s RC, MA 1998 -/85 -/87 Involuted 
7 2/37 2001 LLL s RC 2003 N/A N/A Awaiting F/U 
RUL s RC 2003 Awaiting F/U 
Involuted = AVM markedly reduced in size on CT or no flow during diagnostic angiogram; Loc = PAVM 
location: LLL = left lower lobe; RLL = right lower lobe; RUL = right upper lobe; tAVM = total PAVMs 
occluded; Overall Reperfusion = total # AVMs reperfused/ total AVMs occluded; Reocclusion Date = 
date patient underwent re-embohzation of reperfused PAVM; Reperfusion Type = vessel/AVM found 
on follow-up to be recanalized (RC), to have a missed accessory vessel (MA), or to have developed 
collateral reperfusion (CR), see text; Treatment Date = date of initial occlusion of PAVM; Type = PAVM 
type: S- simple. C- complex, see text; s02 = 02 saturation (%). 
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Table 10. Complications During and After Transcatheter Embolization in 15 Children 
Pt 
TCE 
Date Complication Sequelae Resolution 
FOCAL 
3 1992 Pleurisy, Fever None Complete 
1994 Intra-Procedure Angina None Complete 
4 1987 Fever None Complete 
6 1987 Lost Coil to Right Ventri.de None Asymptomatic 
1994A Unusual Body Pam PTSD Complete 
2000 Pleurisy None Complete 
7 2002 Pleurisy, Headache, Nausea, Vomiting None Complete 
10 1992 Pleurisy None Complete 
1992 Pleurisy None Complete 
1999 Pleurisy None Complete 
11 1992 Pleurisy, Fever None Complete 
21 2002 Pleurisy None Complete 
22 1999 Coil Lost in Lung and Retrieved None Complete 
28 2000 Pleurisy None Complete 
2001 Pleurisy None Complete 
DIFFUSE 
1 1983 Pleurisy None Complete 
2 1991 Pleurisy None Complete 
1993 Pleurisy, Fever None Complete 
3 1991 Pleurisy, Pleural Friction Rub None Complete 
4 1990 Transient Intra-Procedure Leg PainB None Complete 
5 1997 Pleurisy None Complete 
7 1998 Pleurisy None Complete 
8 1999 
c 
Mild Right-Sided Brachial Plexus Injury Right Arm Weakness Complete 
9 2000 Pleurisy None Complete 
11 2001 Pleurisy, Fever None Complete 
A 
Coils and glue used for RUL AVM, patient experienced generalized pain and subsequently developed 
post-traumatic stress disorder (PTSD). 
BMay have been related to sheath in common iliac vein; sheath was removed and pain resolved. Contrast 
injection revealed no anatomical abnormalities. 
(' 
Four-hour procedure with extensive lateral fluoroscopy, requiring hand and arm over head. Weakness and 
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